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Abstract 
The L-type neutral amino acid transporter 1 (LAT1/SLC7A5) is one of 7 light chains 
that can form a heteromeric amino acid transporter (HAT) with the type II single pass 
glycoprotein CD98hc (SLC3A2). LAT1-CD98hc transports essential amino acids and 
some of their catabolites, such as tryptophan, methionine and kynurenine, across 
the plasma membranes of normal and cancer cells. It is also a drug transporter, 
carrying drugs such as gabapentin and L-DOPA across the blood brain barrier. The 
atypical heterodimeric nature of LAT1-CD98hc and its role in disease and drug 
delivery, motivate the structural characterisation of the HAT. Sequence analysis 
revealed two putative cholesterol binding motifs conserved between dDAT and LAT1 
as well as 32 putative CRAC/CARC motifs. The crystal structures of various bacterial 
homologues of LAT1 were used for structure prediction, in order to visualise these 
putative cholesterol binding motifs and assess their plausibility. Here is presented 
the first binding mode analysis of ligands to the inward facing occluded conformation 
of LAT1. Substrates had lower predicted free energies of binding to the inward facing 
conformation compared to the outward open. The putative gating residue F252 may 
play a role in binding to aromatic substrates via p-p stacking in the outward open 
conformation and with all substrates via p-cation bonding with their amino termini 
in the inward facing occluded conformation. Based on the docking analysis, inhibitors 
of LAT1, JPH203 and SKN203 are predicted to transportable substrates of the 
transporter and KMH233 a non-transportable competitive inhibitor with a unique 
binding mode.   LAT1 was overexpressed in HEK293 cells and co-purified with CD98hc 
to a sufficient biochemical homogeneity for structural characterisation. The role of 
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cholesterol hemisuccinate in stabilizing detergent solubilized LAT1-CD98hc was 
established. Detergent solubilized and purified LAT1-CD98hc was subject to 
structural analysis by single particle electron cryo-microscopy to a resolution of 12 Å. 
Multibody 3D auto-refinement and principal component analysis revealed flexibility 
and limited interaction between CD98hc ectodomain and LAT1, contrary to 
predictions based on homology to LAT2-CD98hc. Docking of CD98hc allowed for 
visualisation and generation of molecular movies of the structural dynamics of LAT1-
CD98hc ectodomain, based on these the ectodomain of CD98hc seems tethered to 
LAT1 via the inter-subunit disulphide bond and interaction between their 
transmembrane domains. 
  
 5 
 
 
Table of Contents 
Acknowledgements .................................................................................................1 
Abstract ...................................................................................................................3 
List of Figures ...........................................................................................................7 
List of Tables ..........................................................................................................11 
List of movies .........................................................................................................12 
List of Abbreviations ..............................................................................................12 
Chapter 1 – Introduction ........................................................................................14 
INTRODUCTION TO LAT1-CD98hc ................................................................................. 15 
LAT1-CD98hc - its role in normal and disease physiology ....................................................... 16 
LAT1-CD98hc as a tumour biomarker in various cancers. ....................................................... 21 
LAT1 as a target for tumour imaging markers and radiotherapy development ....................... 23 
LAT1-CD98hc as a target for antitumor chemotherapeutic development ............................... 24 
LAT1-CD98hc as a drug transporter. ...................................................................................... 26 
Biochemical and structural properties of LAT1-CD98hc.......................................................... 27 
HETEROLOGOUS EXPRESSION OF HATS FOR STRUCTURAL STUDY ............................... 32 
INTRODUCTION TO SINGLE-PARTICLE RECONSTRUCTION USING CRYO-ELECTRON 
MICROSCOPY ............................................................................................................... 34 
Sample preparation and data collection. ............................................................................... 38 
Data processing and single particle reconstruction in cryo-EM............................................... 41 
Negative stain single particle reconstruction of LAT2-CD98hc and insights into quaternary 
structure of heterodimer. ..................................................................................................... 45 
OBJECTIVES .................................................................................................................. 47 
Chapter 2 – Materials and Methods ......................................................................48 
Prediction of cholesterol binding/interaction sites by sequence analysis ............................... 49 
Comparative modelling and validation of LAT1 in outward facing open and inward facing 
occluded conformations ....................................................................................................... 50 
Docking of LAT1 ligands in LAT1 models ................................................................................ 53 
Cell culture ........................................................................................................................... 54 
Stable cell-line development ................................................................................................. 55 
Immunoblotting .................................................................................................................... 56 
Radio ligand transport assays ................................................................................................ 57 
Protein purification ............................................................................................................... 58 
Determining optimal conditions for CD98hc deglycosylation ................................................. 59 
Determining the effect of sodium aurothiomalate hydrate on the reduction of the inter-
subunit disulphide bond of LAT1-CD98hc .............................................................................. 59 
Optimisation of detergent concentration, detergent to protein ratio and DDM to CHS ratio in 
membrane solubilisation stage of protein purification ........................................................... 61 
Optimisation of size-exclusion buffer for protein purification ................................................ 61 
Characterisation of the kinetic and thermodynamic stability of LAT1-CD98hc by SE-HPLC ...... 63 
Cryo-EM data collection and processing ................................................................................ 64 
Interpretation of Coulomb potential maps produced by single particle reconstruction .......... 65 
Statistical tests ...................................................................................................................... 70 
 6 
Chapter 3 - Sequence analysis, comparative modelling and docking of LAT1 ........71 
PREDICTION OF MODULATORY EFFECT AND BINDING OF CHOLESTEROL TO LAT1 BY 
SEQUENCE ANALYSIS AND COMPARATIVE MODELLING ............................................... 72 
EXPLORING LAT1 INHIBITOR BINDING BY IN SILICO DOCKING INTO OUTWARD FACING 
AND INWARD FACING MODELS OF THE TRANSPORTER ............................................... 81 
CONCLUSION ................................................................................................................ 91 
Chapter 4 - Overexpression, purification and biophysical characterisation of LAT1-
CD98hc ...................................................................................................................95 
LAT1 OVEREXPRESSION AND STABLE CELL-LINE DEVELOPMENT .................................. 96 
STABILIZATION AND PURIFICATION OF LAT1-CD98hc .................................................. 97 
DEGLYCOSYLATION OF PURIFIED LAT1-CD98hc ............................................................ 99 
OPTIMISATION OF LAT1-CD98hc PURIFICATION BY IMMUNOAFFINITY PRECIPITATION
 ................................................................................................................................... 101 
OPTIMIZATION OF SIZE-EXCLUSION BUFFER FOR PURIFICATION ............................... 103 
CONCLUSION .............................................................................................................. 106 
Chapter 5 - LAT1-CD98hc structure determination by single particle cryo-EM .... 108 
OPTIMISATION OF SAMPLE PREPARATION, IMAGE PROCESSING AND CRYO-EM DATA 
COLLECTION ............................................................................................................... 109 
SINGLE PARTICLE RECONSTRUCTION AND EM DENSITY MAP INTERPRETATION ........ 114 
CONCLUSION .............................................................................................................. 126 
Chapter 6 - General discussion & future outlook ................................................. 128 
References ........................................................................................................... 139 
 
  
 7 
List of Figures 
 
Figure 1 - Summary LAT1-CD98hc gene regulatory network. ..................................19 
Figure 2 – LAT1-CD98hc at the centre of cancer diagnosis and treatment. .............26 
Figure 3 - Schematic of alternative access mechanisms of secondary active LeuT 
transporters.. .........................................................................................................29 
Figure 4 - Topology of LAT1-CD98hc heterodimer. Transmembrane domains are 
shown as rectangles in the plasma membrane (PM). ..............................................29 
Figure 5 - Top (a) and side (b) views of the X-ray crystal structure of monomeric 
CD98hc ectodomain (PDB ID:2DH2).. ......................................................................31 
Figure 6 - Single particle cryo-EM sample preparation, data collection and 
processing. .............................................................................................................37 
Figure 7 - Physical limitations on cryo-EM specimen preparation. ..........................38 
Figure 8 - Negative stain cryo-EM structure of LAT2-CD98hc. .................................45 
Figure 9 - Sequence alignment of LAT1 and AdiC used for homology modelling......51 
Figure 10 - Sequence alignment of LAT1 and GkApcT used for homology modelling.
 ...............................................................................................................................52 
Figure 11 - 2D structures of some of the ligands docked into LAT1 models of the 
outward open and inward facing occluded conformations. ....................................54 
Figure 12 - pcDNA3.1/V5-His TOPO expression vector used for stable cell-line 
development.. ........................................................................................................56 
Figure 13 - General single particle cryo-EM data processing workflow. ...................65 
Figure 14 - Distance restraints as used in docking of LAT1 apo-out open model with 
CD98hc ectodomain crystal structure using the ClusPro server.. ............................67 
Figure 15 - Soft masks used for multibody refinement............................................70 
 8 
Figure 16 - Sequence alignment of dDAT and LAT1. ................................................73 
Figure 17 - Sequence alignment of LAT1 orthologues. ............................................74 
Figure 18 – Quality assessment of local structure prediction for LAT1 models before 
and after refinement by ModRefiner. .....................................................................76 
Figure 19 - Putative cholesterol binding sites on 3D model of LAT1. .......................79 
Figure 20 - Putative CRAC/CARC motifs visualized on model outward facing 
conformation of LAT1. ............................................................................................81 
Figure 21 - Slice through models of the outward facing open and inward facing 
occluded conformations of LAT1. ...........................................................................82 
Figure 22 - Alignment of LAT1 homology models and their putative binding site 
residues. .................................................................................................................84 
Figure 23 - Trends in molecular weight and predicted binding energy. ...................86 
Figure 24 - Ligand docking onto outward open model of LAT1................................87 
Figure 25 - Inhibitor docking onto inward open model of LAT1. ..............................88 
Figure 26 - Stable over-expression of functional LAT1-CD98hc in HEK293SG cells.. .97 
Figure 27 - Immuno-affinity purification of LAT1-CD98hc.. .....................................98 
Figure 28 - The effect of ATM in lysis buffer on reduction of the HAT disulphide 
bond. ......................................................................................................................99 
Figure 29 - Analysis of CD98hc glycosylation using purified LAT1-CD98hc and 
deglycosylase enzymes, PNGase F and Endo H. .................................................... 100 
Figure 30 - Optimization of membrane solubilization step of LAT1-CD98hc 
purification. .......................................................................................................... 102 
Figure 31 - The effect of leucine on the yield and thermal stability of LAT1-CD98hc.
 ............................................................................................................................. 104 
 9 
Figure 32 - Optimization of the buffer for size-exclusion chromatography.  .......... 105 
Figure 33 - Characterization of LAT1-CD98hc kinetic and thermal stability by SE-
HPLC. (a) Stability of LAT1-CD98hc at 4 °C was monitored for 7 days after 
purification by SE-HPLC.  (b) The chromatograms of the HAT after heating for 10 
minutes at the indicated temperatures. Thermal profiles of LAT1-CD98hc in SEC1 
buffer in the absence (c) or presence (d) of 50 mM leucine. ................................. 106 
Figure 34 - Exploratory cryo-EM micrographs of LAT1-CD98hc purified in SEC2 (a) or 
SEC1 (b) buffer obtained at the LMB. Samples were concentrated to 1.1 mg mL-1 
before application to cryo-grid, blotting and plunge freezing. Images were subject 
to 2x2 binning and CTF correction, scale bar shown is 100 nm. ............................ 110 
Figure 35 - Representative aligned micrograph movies of first large dataset of LAT1-
CD98hc in SEC2 at (a) ~3.6 and (b) ~2 µM defocus. ............................................... 112 
Figure 36 - 2D classes of empty detergent micelles and protein detergent 
complexes from the first large dataset of LAT1-CD98hc in SEC2.  ......................... 113 
Figure 37 - Representative aligned micrograph movies of LAT1-CD98hc in 5% 
glycerol and x1 CMC of DDM at (a) ~1.2 and (b) ~3.4 µM defocus. ....................... 116 
Figure 38 - Impact of Volta phase plate data on image contrast of LAT1-CD98hc in 
5% glycerol and x1 CMC of DDM........................................................................... 117 
Figure 39 - Representative aligned micrographs movies of LAT1-CD98hc in glycerol 
free buffer at x1 CMC of DDM collected using Volta phase plate.. ........................ 118 
Figure 40 - Representative 2D classes from glycerol free sample collected using 
Volta phase plate. ................................................................................................. 119 
Figure 41 - 12 Å reconstruction of apo-LAT1-CD98hc in glycerol-free buffer.. ....... 119 
 10 
Figure 42 - Quality of dataset 4 and orientation distribution of 2D projections used 
in single particle reconstruction of LAT1-CD98hc to 12 Å. ..................................... 120 
Figure 43 - Modelling conformations of residues 109 – 112 of the CD98hc 
ectodomain crystal structure (PDB ID 2DH2), where disulphide bond forming C210 
in CD98hc is located. . .......................................................................................... 120 
Figure 44 – Putative LAT1-CD98hc interface residues. .......................................... 122 
Figure 45 - CD98hc ectodomain crystal structure docked in improved EM map 
density. ................................................................................................................ 123 
Figure 46 - Molecular dynamics of LAT1-CD98hc in solution. ................................ 124 
Figure 47 - Distances between residues predicted to be in close proximity based on 
homology to LAT2.  ............................................................................................... 125 
 
  
 11 
List of Tables 
Table 1 - Top 5 hits for LAT1 templates from the HHpred server.............................50 
Table 2 - Summary of suitable homology templates for modelling LAT1. ................52 
Table 3 - Experimental conditions trialed for deglycosylation of CD98hc. ...............60 
Table 4 - Experimental conditions tested during the optimization of the 
solubilization stage of the purification. ...................................................................62 
Table 5 - Experimental conditions tested during the optimization of the 
solubilization stage of the purification. ...................................................................63 
Table 6 - Summary of cryo-EM data collection. .......................................................66 
Table 7 - Predicted dimer interface residues based on EM density map docking of 
CD98hc ectodomain crystal structure and apo-out open LAT1 model. ....................67 
Table 8 - Residues predicted at the interface of LAT2 and CD98hc ectodomain from 
in silico docking and the corresponding residues in LAT1. .......................................69 
Table 9 - Global DOPE scores and dihedral angle analysis for homology modelling. 
Ramachandran plot analysis values are given as number of residues in favoured/ 
allowed/outlier regions of the Ramachandran plots. ..............................................77 
Table 10 - CRAC/CARC motifs identified in the primary sequence of LAT1. .............80 
Table 11 - Predicted binding energies of LAT1 ligands at the putative substrate 
binding sites of homology models in the outward facing and the inward facing 
conformations. .......................................................................................................86 
Table 12 - LAT1 transport inhibitors and their IC50s ...............................................91 
Table 13 - Residues cross-linked in order to validate in silico docking of LAT2 and 
CD98hc ectodomain crystal structure. .................................................................. 125 
 12 
List of movies 
 
Movie 1 ……………………………………………………….https://youtu.be/FhEPXdU9Bu4 
Movie 2…………………………………………………………https://youtu.be/bH5CgIpwhsU 
Movie 3…………………………………………………………https://youtu.be/YvZ0p1dt-Hw  
 
List of Abbreviations 
 
18F-FBPA – 4-borono-2-18F-fluoro-phenylalanine 
AhR – aryl hydrocarbon receptor 
Ar – atom mass in Daltons 
BBB – blood brain barrier 
BCH – 2-aminobicyclo-[2,2,1]-heptane-2-carboxylic acid 
BNCT – boron neutron capture 
BPA – 4-borono-L- phenylalanine 
CARC – CRAC-like motifs 
CHAPS – 3-((3-cholamidopropyl) dimethylammonio)-1-propanesulfonate 
CHS – cholesterol hemisuccinate 
CRAC – cholesterol recognition/interaction amino acid consensus 
cryo-EM – cryo-electron microscopy 
CTF –   contrast transfer function 
dDAT – Drosophila Melanogaster dopamine transporter 
DED – direct electron detectors 
DDM – n-dodecyl beta maltoside 
DOF – depth of field 
EM – electron microscopy 
FDG – fluorodeoxyglucose 
 13 
HAT – heteromeric amino acid transporter 
HBBS – Hank’s Balanced Salt Solution 
HEK293 – human embryonic kidney cell-line 
HEK293SG – human embryonic kidney cell-line, suspension adapted and N-
acetylglucosaminyltransferase I deficient 
IDO – indoleamine 2,3-dioxygenase (IDO) 
LAT1 – L-type neutral amino acid transporter 1 
LAT2 – L-type neutral amino acid transporter 2 
LMNG – lauryl maltose neopentyl glycol 
mTORC1 – mechanistic target of rapamycin 
PCA – principal component analysis 
PET – positron emission tomography 
SE-HPLC – size exclusion high pressure liquid chromatography 
SLC – solute carrier  
SNR – signal to noise ratio 
TBS – Tris buffered saline 
TBST - Tris buffered saline with Tween 
TDO – tryptophan 2,3 dioxygenase  
TEM – transmission electron microscopy 
T3 – triiodothyronine 
TM – transmembrane helix 
VPP – Volta phase plate  
 14 
 
 
 
 
 
 
Chapter 1 – Introduction 
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This chapter introduces the transporter that is the subject of this thesis, its 
physiological roles and clinical significance. Background on its biochemistry is also 
given. The main technique, around which many of the experiments are geared, cryo-
electron microscopy is introduced in this the chapter. The objectives of the study are 
given at the end of chapter. 
 
INTRODUCTION TO LAT1-CD98hc 
Heterodimeric amino acid transporters (HATs) are rare among the estimated 
400 solute carrier (SLC) transporter genes annotated in the human genome 
(Schlessinger et al., 2010). There are 7 HATs with subunits belonging to the SLC3 and 
SLC7 gene families. SLC3A1 and SLC3A2, the heavy chains, are type II single pass 
transmembrane glycoproteins that act as chaperones for the transport active light 
chains of some members of the SLC7 family. SLC3A2, also known as CD98hc or 4F2hc, 
forms heterodimers with SLC7A5 – 8 and SLC7A10 – 11, while SLC3A1 only complexes 
with SLC7A9. Within the HATs, the two subunits are linked together by a disulphide 
bridge between a conserved cysteine in the loop between transmembrane helices 3 
and 4 of the light chain and a cysteine in the heavy chain. All HATs function as 
obligatory exchangers/antiporters exchanging one substrate for another (Devés and 
Boyd, 2000; Reviewed by Fotiadis, Kanai and Palacín, 2013). 
The L-type amino acid transporter 1/SLC7A5 (LAT1) is a 55 kDa polytopic 
integral membrane protein that has been shown to function as a Na+-independent 
secondary active antiporter of neutral L-amino acids and in some cases their 
catabolites. Substrates of LAT1 include leucine, isoleucine, valine, phenylalanine, 
tyrosine, tryptophan, methionine and histidine (Kanai et al., 1998; Mastroberardino 
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et al., 1998). CD98hc is 68 kDa and functions as a chaperone for LAT1, stabilizing and 
facilitating its translocation to the plasma membrane (Nakamura et al., 1999).   
 
LAT1-CD98hc - its role in normal and disease physiology 
LAT1 is expressed in a number of tissues throughout the body, namely the 
foetal liver, placenta, brain, testis, bone marrow, and leucocytes, in descending 
magnitude of expression, whereas CD98hc seems to be expressed more ubiquitously 
(Yanagida et al., 2001). The expression of LAT1-CD98hc at the placenta has been 
suggested to be essential for the development of the foetus because of the 
transporter’s role in the uptake of essential amino acids and thyroid hormones 
(Ritchie and Taylor, 2001). The catabolism of tryptophan, a substrate of LAT1-
CD98hc, by indoleamine 2,3-dioxygenase (IDO) to kynurenine, which is also a LAT1-
CD98hc substrate, in the placenta has been shown to play a role in the suppression 
of the maternal immune system, preventing the rejection of the foetus because it is 
allogenic (Tafuri et al., 1995; Sinclair et al., 2018). An increasing number of tumours 
have been shown to ectopically express the LAT1-CD98hc complex (Cantor and 
Ginsberg, 2012; Zhao et al., 2015). It is hypothesised that CD98hc plays a similar role 
in cancer cells as in lymphocyte activation, which is the amplification of b1 and b3 
integrin signalling, reducing anchorage dependence and promoting cell proliferation 
by modulating cyclin dependant kinase regulation through extracellular signal-
regulated kinase signalling (Cantor and Ginsberg, 2012). LAT1-CD98hc interacts 
directly with b1 integrins in a CD98hc dependant manner, this occurs particularly in 
ordered lipid microdomains (Kolesnikova et al., 2001). The mechanism by which this 
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complex plays its role in lymphocyte activation remains to be elucidated (Cantor and 
Ginsberg, 2012). LAT1 is responsible for the transporter activity of the HAT, an 
activity that has also been shown to be pro-tumorigenesis (Napolitano et al., 2015). 
The substrates that LAT1 supplies, are essential amino acids, necessary for protein 
synthesis and the replenishment of tricarboxylic acid cycle intermediates used in the 
synthesis of other macromolecules, necessary for the survival and dysregulated 
proliferation of tumour cells (DeBerardinis et al., 2007). Leucine, a substrate of LAT1, 
is sensed by sestrin2 leading to the activation of mechanistic target of rapamycin 
complex 1 (mTORC1), which in turn promotes growth while inhibiting autophagy 
(Saxton et al. 2016; Nicklin et al. 2009). The mechanistic target of rapamycin pathway 
has been identified as a key regulator of both aerobic glycolysis and protein 
synthesis, which have been highlighted in the “hallmarks of cancer” (DeBerardinis et 
al., 2008; Hanahan and Weinberg, 2011). LAT1-CD98hc is expressed and essential for 
the differentiation of activated T-lymphocytes during an adaptive immune response, 
providing another potential mechanism by which the transport function of LAT1-
CD98hc is beneficial to the progress of cancer (Cantor and Ginsberg, 2012; Sinclair et 
al., 2013). mTORC1 plays a role in T cell antigen response, by reprogramming the 
metabolism of the cell for increased protein synthesis and proliferation, both of 
which are mediated by the upregulation of LAT1 in response to the engagement of T 
cell antigen receptor. Another downstream effector of the T cell antigen receptor is 
the MYC family of transcription factors which regulate transcription of mRNA for 
proteins necessary in the metabolic reprograming of characteristic of T cell 
differentiation such as the glucose transporter GLUT1 (Jones and Thompson, 2007) 
(Figure 1). Glioma cell-lines have been shown to produce the tryptophan catabolite, 
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kynurenine, which suppresses T cell proliferation (Frumento et al., 2002). Kynurenine 
is transported by LAT1-CD98hc and an agonist of the aryl hydrocarbon receptor 
(AhR), which binds to a DNA binding element in intron 2 of the LAT1 gene, recruiting 
p300, a histone acetyltransferase, that promotes LAT1 gene transcription (Lo and 
Matthews, 2012). Taken together with the fact that the enzyme that catalyses the 
rate-limiting step in the synthesis of kynurenine in glioma cells, tryptophan-2,3-
dioxygenase, is itself regulated by AhR, LAT1-CD98hc is at the centre of an 
autocrine/paracrine signalling network that allows cancers cells to modulate immune 
responses to their advantage (Opitz et al. 2011; Kaper et al. 2007; Tomblin et al. 
2016). This complex signalling network and its role in cancer remains to be further 
and definitively elucidated (Figure 1).   
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Figure 1 - Summary LAT1-CD98hc gene regulatory network. LAT1-CD98hc is a secondary active 
antiporter ectopically expressed in several cancers. The antiporter translocates essential amino acids 
(EEA) (pink circles), such as leucine and tryptophan and some of their catabolites such as kynurenine 
(dark blue circles), across the cell membrane. The MYC family of proto-oncoproteins upregulates LAT1 
expression which in turn upregulates MYC protein synthesis in a feed-forward loop that drives tumour 
proliferation in cancer. EEA are substrates for protein synthesis and the synthesis of precursors for 
other macromolecules so therefore sustain tumour growth. Leucine has been shown to facilitate the 
activation of mTORC1 which promotes growth via increased mRNA translation while inhibiting 
autophagy. Kynurenine is an agonist of the AhR which upregulates the expression of TDO and LAT1, 
thereby increasing kynurenine synthesis, transport of tryptophan into and kynurenine out of the cell. 
Kynurenine is taken up by T-cells via LAT1 resulting in their suppression, allowing cancer cells to escape 
destruction by them.  
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LAT1-CD98hc is regulated by several proto-oncogenes, suggesting alternative 
pathways for its ectopic expression in tumours. An example of this is the regulation 
of LAT1 by AhR, whose ligands can be either be pro- or anti-tumorigenic as has been 
mentioned above (Safe et al., 2017). Recruitment of the AhR-ARNT complex to the 
LAT1 gene was demonstrated to increase proliferation in breast cancer cell-lines 
(Tomblin et al., 2016). HIF2a has also been implicated in cancer as part of the 
mechanism through which the oxygen sensing pathways can promote oncogenesis. 
HIF2a upregulates the expression of LAT1, by binding to hypoxia response elements 
in the promoter and intron 1 of the LAT1 gene, which in turn leads to the activation 
of mTORC1 as described above (Elorza et al., 2012). MYC proteins are another 
example of proto-oncogenes that have been demonstrated to regulate the 
expression of LAT1 by, after dimerization with MAX, binding directly to the MYC 
consensus motif (E-box) in promoter of the LAT1 gene (Adhikary and Eilers, 2005; 
Hayashi et al., 2012; Yue et al., 2017). The expression of C-MYC in tumours has been 
shown to correlate with the expression of both LAT1 and CD98hc (El Ansari et al., 
2018b; a). Knock-down or inhibition of LAT1 results in lower N- and C-MYC expression 
suggesting a feed forward loop between the transporter and oncogenes that drives 
tumorigenesis (Figure 1). In addition to the downregulation of MYC proteins in 
response to LAT1 inhibition, cell cycle regulator, cyclin D1 and cell death regular, 
BCL2 were also downregulated, further elaborating the mechanism by which LAT1 
promotes tumour growth and survival. (Yue et al., 2017). There remains work to be 
done in further characterising the regulation of LAT1-CD98hc and how the HAT in 
turn influences the expression and activity of other oncogenes in cancer. The focus 
above has been on the regulation of LAT1 expression since it has been shown that 
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CD98hc is upregulated in response to LAT1 upregulation (Khunweeraphong et al., 
2012; Cormerais et al., 2016). 
LAT1 and CD98hc both have activities that promote tumour growth, with the 
transport activity of their HAT suggested to be the main mechanism by which the 
complex promotes cancer and this is summarised in Figure 1 (Cormerais et al., 2016).  
At present there is limited information about this mechanism at the atomic level, 
something that is hindering progress in the exploitation of LAT1-CD98hc for the 
diagnosis, management and treatment of cancer.  
 
LAT1-CD98hc as a tumour biomarker in various cancers. 
Molecular and genetic biomarkers offer a robust and reproducible means of 
diagnosing cancer, choosing the best treatment and or management options as well 
as predicting the outcomes of these clinical strategies for patients. Tumour 
biomarkers can also play an important role during drug development by allowing for 
stratification of clinical trial participant cohorts and in measuring the efficacy of the 
potential therapeutic under development. Ideally a good tumour biomarker allows 
for distinction between benign and malignant neoplasia, can be quantitively 
correlated with the degree of malignancy and lastly, can be assayed with relative 
ease and robustness. LAT1-CD98hc, being expressed in a small number of tissues in 
normal physiological conditions while also being ectopically expressed in tumours, 
makes a good candidate for a tumour biomarker (Figure 2). Evidence to support this 
hypothesis is building. For example, LAT1 has been shown to be upregulated in breast 
cancer, with high LAT1 expression levels being correlated with tumour size, tumour 
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grade and patient survival outcome. Furthermore, LAT1 is differential expressed 
between the various breast cancer types and the subtypes within them. For example 
in estrogen receptor positive breast cancer, LAT1 expression levels correlate with the 
proliferation phenotype of the tumour, with LAT1 expression being higher in luminal 
B compared to A malignancies (El Ansari et al., 2018b). Similar observations have 
been made with respect to CD98hc in breast cancer (El Ansari et al., 2018a). 
 Three more examples of where LAT1-CD98hc is a potentially effective tumour 
marker, are in stratification of glioblastomas, the diagnosis of prostate cancer and as 
a predictor of resistance to chemotherapy in pancreatic ductal adenocarcinoma. High 
grade gliomas have been shown to express high levels of LAT1 whereas expression is 
barely detectable in low grade gliomas (Nawashiro et al., 2005; Kobayashi et al., 
2008). In addition to being a potentially good biomarker for high grade gliomas, LAT1 
is highly expressed in infiltrating gliomas, which are often difficult to remove entirely 
by surgery, making LAT1 a good target for the development of adjuvant 
chemotherapeutics (Nawashiro et al., 2005; Kobayashi et al., 2008). In prostate 
cancer LAT1 immunohistochemical staining has been shown to be a potentially useful 
supplement to prostate specific antigen blood tests, for routine screening, and to the 
Gleason score for malignancy grading. In cases of inoperable prostate cancer, 
patients with high LAT1 expression have a poor prognosis, with most of them living 
less than 5 years after the first biopsy examination (Sakata et al., 2009). Finally, high 
expression of LAT1 was found to correlate negatively with responsiveness to 
adjuvant and systemic chemotherapy in pancreatic ductal adenocarcinoma (Altan et 
al., 2018). 
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 Despite various strands of evidence supporting the development of LAT1-
CD98hc as a tumour biomarker, clinical trials are required before it can be integrated 
as a biomarker in clinical practice and drug development.  
 
LAT1 as a target for tumour imaging markers and radiotherapy development 
Positron emission tomography (PET) is useful for non-invasive biological 
imaging that can be used in conjunction with other imaging modalities such as 
computed tomography, facilitating the diagnosis, staging and treatment of cancer 
(Griffeth, 2005). PET is often used to exploit metabolic changes that occur during the 
development and progression of cancer, as is the case with the popular tracer 18F-
fluorodeoxyglucose (FDG), which targets changes in energy metabolism (d’Amico, 
2015). Given the variety of physiological and pathophysiological states that affect  
glucose metabolism, such as activity in the brain or inflammation, PET using FDG is 
prone to high imaging background and false positives thus amino acid PET tracers 
have been developed and used, giving lower background signal while showing 
preferential accumulation in malignant tumors (Jager et al., 2001).  The expression 
of LAT1 in a small number of normal tissues and upregulation in a large number of 
tumors, make it an ideal transporter to target for the development of PET tracers 
(Figure 2) (Wei et al., 2016; Nodwell et al., 2017). L-3-18F-a-methyl tyrosine is one 
such example of a LAT1 specific PET tracer that has shown effectiveness in clinical 
trials, preferentially accumulating in malignant tumors rather than in benign 
neoplasia or normal tissue, as a result functions as an effective prognostic marker in 
non-small cell lung carcinoma (Wiriyasermkul et al., 2012). 
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Boron neutron capture therapy (BNCT) is a radiotherapy that has been used 
against high grade gliomas (Barth et al., 2012). It is dependent on the presence of 
10B, which can be delivered to and enriched in the tumour tissue relative to normal 
tissue, using 4-borono-L- phenylalanine (BPA).  4-borono-2-18F-fluoro-phenylalanine 
(18F-FBPA) was developed to allow the estimation of BPA accumulation in tumour 
tissues using non-invasive PET scanning. The accumulation of 18F-FBPA was shown to 
correlate with LAT1 expression, which was not surprising given that both 18F-FBPA 
and BPA are LAT1 substrate analogues (Yoshimoto et al., 2013). The use of 18F-FBPA 
accumulation in tumour cells as a predictor of BPA accumulation in cells, can be 
useful in predicting outcomes BNCT in patients. 
The targeting of LAT1 for the development of radio-imaging tracers and for 
the delivery of targeted radiotherapy, is an area that has not been fully explored. The 
examples of where this has been done are all based on mimicking known natural 
substrates of LAT1. Structural characterisation of LAT1 may enable different 
approaches to exploit the ectopic expression of the transporter for imaging and 
radiotherapy in various cancers. 
 
LAT1-CD98hc as a target for antitumor chemotherapeutic development 
LAT1 was determined, through transport inhibition assays, to be the 
serendipitous target of the chemotherapeutic melphalan (Uchino et al., 2002). This 
is consistent with a later finding that LAT1 expression is a significant prognostic 
indicator for the success of melphalan treatment of multiple myeloma (Isoda et al., 
2014). When overexpressed, LAT1-CD98hc promotes growth of low level tumour 
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cells and inhibiting it using 2-aminobicyclo-[2,2,1]-heptane-2-carboxylic acid (BCH) 
has cytostatic and chemotherapeutic effects on tumour cells, providing further 
evidence of the HAT’s potential as a drug target (Kobayashi et al., 2008). Using a 
canine model of melanoma, it was demonstrated that the cytostatic effect of 
chemotherapeutics such as carboplatin and doxorubicin for example, can be 
enhanced by inhibiting LAT1 using BCH or melphalan (Fukumoto et al., 2013). 
Another inhibitor of LAT1, JPH203, was designed using the thyroid hormone T3 as a 
scaffold (Figure 2). JPH203 has been shown to inhibit leucine uptake, growth and 
induce apoptosis in cancer cells. It is potentially a high affinity inhibitor of LAT1-
CD98hc, with IC50 as low as 0.14 and 0.06 µM (Oda et al., 2010; Yun et al., 2014; Choi 
et al., 2017). The inhibitor is currently in phase I clinical trials for solid tumours. Two 
other LAT1 inhibitors have been developed and validated in vitro, these are SKN103 
and KMH233. They are still to be tested for safety and efficacy in animal models and  
in human (Huttunen et al., 2016; Kongpracha et al., 2017).   
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LAT1-CD98hc as a drug transporter. 
LAT1-CD98hc’s importance as a target for small molecule drug development 
extends beyond chemotherapeutics. The HAT has been shown to transport drugs like 
L-DOPA and gabapentin across the blood brain barrier (BBB) (Kageyama et al., 2000; 
Dickens et al., 2013). This is worth noting since it is estimated that only 2 % of small 
molecule drugs can cross the BBB, therefore the BBB poses a significant hurdle in the 
development of small molecule therapeutics for neurological diseases (Pardridge, 
 
Figure 2 – LAT1-CD98hc at the centre of cancer diagnosis and treatment. LAT1 (predicted structure) 
and CD98hc (ectodomain crystal structure) shown at the centre of the image function as 
heterodimeric transporter. This transporter has been found upregulated in numerous cancers 
making it a potential biomarker. Through its transport activity, LAT1-CD98hc can facilitate the 
uptake of radiotracers for PET imaging and radio- compounds into cancer cells for the purpose 
diagnosis, prognosis and treatment of tumours. Finally, due to the role of the transporter in cancer 
metabolism it can be targeted for the development of chemotherapeutics.  A detailed knowledge 
of the structure and thence mechanism of the transporter would lead to significant strides in these 
three areas of oncology.  
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2005). The idea of making pro-drugs by conjugating them to LAT1 substrates has 
been put forward and significant efforts made towards achieving this (Rautio et al., 
2013). In one study the drug valproic acid was conjugated to the benzene ring of 
phenylalanine, a LAT1 substrate, in order to make prodrugs with improved BBB 
penetration. All the variants of the valproic prodrugs crossed the BBB with one of the 
meta- substituted versions demonstrating a 10 fold higher affinity and a 2 fold 
increase in transport compared to the other variants (Peura et al., 2011). Another 
approach has been to understand the structure-function relationship of LAT1 by 
determining a pharmacophore for the transporter using in silico structure prediction, 
in vitro transport assays and rat brain perfusion experiments, which in turn informs 
chemical synthesis of potential LAT1 ligands (Killian et al., 2007; Ylikangas et al., 2013, 
2014; Augustyn et al., 2016; Nagamori et al., 2016; Zur et al., 2016; Chien et al., 2018). 
The experimental solution of an atomic structure of LAT1-CD98hc would greatly 
facilitate these efforts as it would give a detailed understanding of how the 
transporter recognises and transports its substrates. 
 
Biochemical and structural properties of LAT1-CD98hc. 
It was suggested based on hydropathy plot analysis of LAT1’s amino acid 
sequence, the HAT light chain was composed of 12 transmembrane helices (TM). 
Association via a conserved disulphide bond between its C164 and C109 of CD98hc 
was also established by sequence analysis and co-immunoprecipitation. Both the N 
and C termini are predicted to be located in the cytoplasm (Figure 4) (Kanai et al., 
1998; Mastroberardino et al., 1998). Homology modelling of LAT1 based on AdiC and 
 28 
ApcT predicts that comprise a LeuT-fold where the first 10 helices adopt a 5 + 5 
inverted repeat with the repeats related by a 2 fold pseudo-symmetry axis and TMs 
11 and 12 wrapping around the edge of the repeats (Dickens et al., 2013; Geier et al., 
2013). LeuT-fold transporters are predicted to carry out transport via the alternative 
access mechanism (Reviewed by Kazmier, Claxton and Mchaourab, 2017) (Figure 3). 
In this mechanism the transporter alternates between being open on one side of the 
membrane, allowing for substrate to bind and being released on the opposite side of 
the membrane as the transporter changes conformation, opening on the opposite 
side (Jardetzky, 1966) (Figure 3). It has been shown that LAT1 operates downstream 
of Na+ dependant transporter such as SLC1A5, which exploit Na+ gradients generated 
Na+/K+ pumps to concentrate LAT1 substrates such as glutamine which are 
exchanged for substrates such as essential amino acids, that the cell cannot 
synthesise (Nicklin et al., 2009). LAT1 has been demonstrated to have asymmetric 
substrate affinities on the extra-  and intracellular binding sites with the Km values on 
the intracellular side being 2 – 3 orders of magnitude lower than on the extracellular 
side, this means that LAT1 acts as an influx transporter for substrates that are at 
lower concentration in the cell than outside (Meier et al., 2002). 
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Figure 3 - Schematic of alternative access mechanisms of secondary active LeuT transporters. It is 
hypothesised and supported by crystal structures that LeuT transporters have a single substrate 
binding site that is either open for substrate (blue/green circles) binding in the outward facing 
conformation the extracellular side (OOp) or inward facing conformation the cytosolic side (IO) of the 
plasma membrane. There are intermediate states, between these two conformations in which the 
substrate binding site is occluded in the outward facing or inward facing direction (OOc and IOc 
respectively). 
 
Figure 4 - Topology of LAT1-CD98hc heterodimer. Transmembrane domains are shown as rectangles 
in the plasma membrane (PM). CD98hc shown in gold and LAT1 in purple. Both termini of LAT1 are 
intracellular and the subunit has no large soluble domains whereas CD98hc has a large extracellular 
N-terminal domain, the ectodomain, a single TM and intracellular C terminus. The inter-subunit 
disulphide bond (red) is located between the loop linking CD98hc’s ectodomain to its TM, and the 
loop between TM3 and 4 of LAT1.  
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Based on radioligand binding assays and comparison of known substrates, it 
was proposed that the negative and positive charges of the carboxyl and amino 
groups were recognised by residues in the substrate binding site while hydrophobic 
interactions were important for recognition of the side chain of a substrate (Uchino 
et al., 2002). The substrate binding site was predicted to be located in the centre of 
the protein, between TM1,TM3, TM6, TM8, TM10, with residues 62 – 66 and 253 – 
255 predicted to recognise the carboxyl and amino groups via hydrogen bonding with 
their Ca backbone, while the hydrophobic side chains of residues like I139, V148, 
F252, F402, W405, interacted with the side chain of the substrate (Geier et al., 2013). 
Evidence that an amino acid group is not a requirement for transport by LAT1 has 
recently come from radioligand transport assay experiments with carboxylic 
acid bioisosteres of the LAT1 substrates (Nagamori et al., 2016; Zur et al., 2016). LAT1 
has also been shown to transport not only L-a amino acids but also D-a, b and g amino 
acids, although physiological relevance for this is still to be established (Nagamori et 
al., 2016; Chien et al., 2018).  The widening of the LAT1 structure-activity relationship, 
made LAT1 an even more valuable target for delivery of small molecule therapeutics 
to tissues expressing it, but also highlights the limits of cellular assays and structure 
prediction in the absence of an experimentally determined atomic models of the 
transporter which allow for a detailed and accurate characterisation at this level of 
the transporter’s structure activity relationship.  
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Figure 5 - Top (a) and side (b) views of the X-ray crystal structure of monomeric CD98hc ectodomain 
(PDB ID:2DH2). CD98hc’s ectodomain bears resemblance to a amylases, with the characteristic A-
domain comprised of a (b/a)8 TIM barrel (red) and a C domain comprised of 8 anti-parallel strands 
folded into a b sandwich. Glycosylated asparagine residues are shown as spheres with N and O atoms 
coloured blue and red respectively. 
CD98hc comprises a 184 amino acid long intracellular C terminal domain, a 
transmembrane helix and a large 424 amino acids long ectodomain (Figure 5), 
(Uniprot ID P08195). The heavy chain is N-link glycosylated at N365, N381, N424 and 
N506, all of which are located in the ectodomain and are solvent accessible (Fort et 
al., 2007; Powlesland et al., 2009). The functional relevance of these glycans remains 
to elucidated. C109, located in a linker between the transmembrane helix and 
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ectodomain of CD98hc, covalently binds  to a conserved cysteine, C164 in the case of 
LAT1, in the loop between TM3 and 4 of the light chains (Kanai et al., 1998; 
Mastroberardino et al., 1998). The ectodomain has an a amylase like fold with A and 
C domains typical for these enzymes but no B domain (Figure 5). Despite the 
similarity, comparative structural analyses, which revealed a lack of key catalytic 
residues and extensive screening of a-glycosidase activity, did not reveal any such 
activity. The ectodomain did not show any signs of glycosylation binding either (Fort 
et al., 2007).  
 
HETEROLOGOUS EXPRESSION OF HATS FOR STRUCTURAL STUDY 
Several attempts at the heterologous expression and purification for 
structural characterisation of CD98hc and several of its light chains have been 
reported in the literature. The structure of the soluble ectodomain of CD98hc, amino 
acids 115-530 (Uniprot ID P08195-2), was determined to 2.1 Å using crystals grown 
from protein expressed in E. coli strain, Rosetta (DE3) pLysS (Figure 5) (Fort et al., 
2007). Galluccio et al., 2013 published a protocol for the expression of LAT1 and 
CD98hc hexa-his and glutathione-S-transferase tagged fusion proteins respectively 
using the same E. coli strain. No obvious attempt at targeting the fusion protein to 
the plasma membrane was made, necessitating recovery from the insoluble fraction 
of the cell lysate, the expressed LAT1.  The detergent sarkosyl, chaotrope, urea and 
reducing agent dithioerythritol were used to do this, before Ni2+ affinity purification, 
during which the sarkosyl was exchanged for triton X100. After purification, using 
glutathione sepharose 4B resin, the GST tag on CD98hc was cleaved off by incubation 
with thrombin and separated by size exclusion chromatography (Galluccio et al., 
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2013). LAT1-CD98hc expressed and purified as described by Galluccio et al., 2013 has 
been reconstituted in proteoliposomes and used in functional transport assays 
(Napolitano et al., 2015, 2017b). Despite the successful structure determination of 
the ectodomain of CD98hc expressed in E. coli, there has been no progress on the 
structural characterisation of the rest of CD98hc with or without any of its associated 
light chains, using this prokaryotic expression system. Palacin and co-workers, who 
had successfully solved the ectodomain structure of CD98hc, proceeded to adopt the 
P. Pastoris system for expression of a complete HAT complex for the purpose of 
structural study. Using DDM for membrane solubilisation and a tandem affinity 
coupled with size-exclusion chromatography purification strategy, enough LAT2-
CD98hc was produced for structural characterisation by negative stain cryo-EM to 21 
Å. A combination of this low-resolution map of the protein complex in detergent, in 
silico modelling and docking, as well mutagenesis and cross-linking experiments, 
revealed insights into the interaction of the ectodomain of CD98hc and LAT2, as 
discussed in detail below (Rosell et al., 2014).  Improvements to the sample 
preparation of LAT2-CD98hc were made using a mixture of DDM, LMNG (lauryl 
maltose neopentyl glycol), CHS (cholesterol hemisuccinate) and glycerol for 
solubilising the HAT complex, yielding a more monodisperse and kinetically stable 
sample for structural studies (Meury et al., 2014).  
LAT1 has previously been expressed in human cells for the purposes of 
characterizing its function and for developing and screening prodrugs and inhibitors 
(Dickens et al., 2013; Zur et al., 2016; Puris et al., 2017; Chien et al., 2018). In addition 
to being able to address functional questions in a human cell-line expression system, 
there is no need to co-express both the light and heavy chains since the ubiquitously 
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expressed heavy chain is upregulated, in response to LAT1 overexpression 
(Khunweeraphong et al., 2012). HEK293 cell-lines are currently the mammalian 
expression system of choice for membrane protein structural biology (Chaudhary et 
al., 2012; Goehring et al., 2014). The first HEK293 cell line was derived in 1973 by the 
transformation of kidney cells from an aborted human embryo, using adenovirus 5 
DNA and other variant cell-lines have since been developed from it including the 
HEK293T and HEK293SG cell-lines (Lin et al., 2014). The HEK293SG cell is useful for 
the production of membrane and glycoproteins for structural biology as it is 
suspension adapted making it easier to grow at the scale necessary and also has a 
loss of  function mutation in N-acetylglucosaminyltransferase I, rendering it 
incapable of complex glycan synthesis (Reeves et al., 2002; Lin et al., 2014). The 
simpler glycans produced by HEK293SG cells are sensitive endoglycosylases like 
EndoH, and are easy to remove if not required after purification. Chaudhary et al., 
have developed a detailed protocol for stable transfection and large-scale 
suspension culture that is easy and cheap to implement (Chaudhary et al., 2012). For 
the work reported here, LAT1-CD98hc was expressed and purified from HEK293SG 
cells and the initial solubilisation and purification conditions were adapted from 
Meury et al., 2014.  
 
INTRODUCTION TO SINGLE-PARTICLE RECONSTRUCTION USING CRYO-
ELECTRON MICROSCOPY 
Transmission electron microscopy (TEM) has been used for the study of 
molecular organization, dating back to the first 3D reconstruction of a biomolecular 
structure by De Rosier and Klug in 1968. This first reconstruction was from a TEM 
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micrograph of phage particles, to a resolution of 35 Å (De Rosier and Klug, 1968). 
Resolutions higher than those estimated to be possible by single particle analysis of 
heavy metal stained samples (>15 Å), (Klug and Berger, 1964; De Rosier and Klug, 
1968) were demonstrated using unstained 2D crystalline samples, by Henderson and 
Unwin, when they solved the structures of bacteriorhodopsin and catalase to 7 and 
9 Å respectively (Henderson and Unwin, 1975; Unwin and Henderson, 1975). More 
recently, from about 2008 and onward, the field has undergone what has been 
described as a “resolution revolution”, with structure determination of biomolecules 
by single particle TEM is at resolutions where atomic details are well resolved (<4Å)  
(Reviewed by Cheng and Walz, 2009; Kühlbrandt, 2014). The impact of this revolution 
was recognised by the award of the 2017 Nobel prize in Chemistry to Richard 
Henderson, Jacques Doubchet and Joachim Frank “for developing cryo-electron 
microscopy for the high-resolution structure determination of biomolecules in 
solution”. 3D single particle reconstruction from 2D projections from TEM 
micrographs of particles in vitreous ice, usually referred to just as cryo-EM in the 
literature, is the particular mode of TEM that has undergone this resolution 
revolution.  
In order to achieve resolutions comparable to X-ray crystallography by cryo-
EM several obstacles have been overcome, namely the interaction of electrons with 
air, the deleterious effects of radiation and the vacuum on biological specimens, and 
the weak phase scattering of atoms typical of biological samples. In order to prevent 
the scattering of the imaging electron beam by air particles, the column of the 
electron microscope is operated under a high vacuum, which can desiccate biological 
specimens destroying the structure of interest. For cryo-EM imaging of biological 
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specimens in high vacuum, the vitrification of the specimen and operation of the 
electron microscope column at cryogenic temperatures, hence the prefix cryo-, was 
developed and is used, preventing desiccation of the specimen (Figure 6) (Dubochet 
et al., 1985). Vitrification also reduces the impact of radiation damage by limiting the 
spread of free radicals from their origin in the sample and also allows for use of higher 
electron doses, than otherwise useful, for data collection (Reviewed by Chiu, 1986). 
The third obstacle mentioned above is the weak phase scattering of electrons by 
biological specimens, which, together with the low electron doses necessary to limit 
radiation damage, result in low contrast images with low signal to noise ratio (SNR) 
(Unwin and Henderson, 1975; Henderson, 1995). In addition to this, inelastic and 
secondary scattering events, which are more common than the signal producing 
elastic scattering events, contribute to the background, lowering the SNR (Figure 7) 
(Henderson, 1995; Angert et al., 1996). The problem of low SNR in cryo-EM data has 
been addressed on the hardware/practical level mainly by the development of direct 
electron detectors, which because of their higher dynamic quantum efficiency, 
contribute less to the noise in the image and higher frame rate, provide more data 
enabling reduction of noise and blurring from other sources such as beam induced 
motion of the specimen. On the processing level, SNR is improved by imaging 
aberration correction, image alignment and averaging techniques, which are 
discussed in more detail below (Frank, 2006; McMullan et al., 2016; Sigworth, 2016). 
With respect to small molecular weight proteins (<400 kDa), which have a lower SNR 
than larger proteins, the Volta phase plate (VPP) has been useful for increasing 
contrast in the micrographs of such samples, facilitating the solution of their 
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structures to high resolution (Danev and Baumeister, 2016; Khoshouei et al., 2016, 
2017).  
The remainder of this section will discuss various stages of structure 
determination by single particle cryo-EM, from sample preparation, data collection 
to data processing summarized in Figure 6. 
 
 
Figure 6 - Single particle cryo-EM sample preparation, data collection and processing. A solution of the 
particle of interest, in this example glutamate dehydrogenase, is applied to a grid, blotted and plunge 
frozen, ideally producing a monolayer of the particle in various orientations, embedded in vitreous 
ice. The specimen is imaged in a TEM microscope producing 2D images of the particle which can be 
analysed to reveal the 3D structure of the particle. Taken from Fernandez-Leiro and Scheres, 2016. 
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Figure 7 - Physical limitations on cryo-EM specimen preparation. a) Possible interaction electron may 
have specimen during imaging. Events are arranged in order of probability from left to right. Phase 
contrast is produced by the interference of the unscattered beam and the elastically scattered while 
inelastic scattering damages the structure of the specimen and all other events don’t contribute to 
the signal but rather to the background. Factors considered in specimen design are shown in b) plotted 
against energy of the imaging electron beam. DOF is depth of field.  Taken from Christopher J. Russo 
and Passmore, 2016. 
 
Sample preparation and data collection. 
Approaches to single particle reconstruction are predicated on the 
assumption that the 2D projections obtained from cryo-EM micrographs are of the 
same particle, differing only in their relative orientations (Reviewed by Sigworth, 
2016). This necessitates that a particle of interest be purified to biochemical and 
conformational homogeneity and be kinetically and thermodynamically stable 
enough for analysis by cryo-EM. In this respect single particle cryo-EM is similar to 
crystallography in its sample requirements and therefore approaches used for the 
purification and stabilization of biomolecular complexes, such as heterologous 
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expression and affinity chromatography are applicable (e.g. Newby et al., 2009). 
Cryo-EM unlike  crystallography  requires smaller amounts of sample, 0.25 pmol vs 
500 pmol, and does not require crystals, facilitating the study of difficult to produce 
and crystallise samples such as membrane proteins (Frank, 2006; Vinothkumar, 
2015). Once purified, negative-stain cryo-EM is often used to assess the quality of 
the sample preparation, allowing for assessment of homogeneity, particle size and 
integrity before moving on to cryo-EM. Buffer components that may increase noise 
(background signal) in cryo-EM micrographs of vitrified samples such as glycerol, 
sucrose or detergent are used sparingly or completely avoided if possible (Passmore 
and Russo, 2016; Thompson et al., 2016).  For imaging in the electron microscope, 
the purified sample is applied to a substrate, often a metal grid supporting a 
perforated substrate such as amorphous carbon,  and blotted to create thin layer of 
liquid which is plunge frozen in liquid ethane (Figure 6) (Cho et al., 2013; Passmore 
and Russo, 2016).  Ideally, micrographs for 3D reconstruction should be collected 
from specimen grids with an ice thickness sufficient to accommodate a monolayer of 
the single particle of interest, in a wide distribution of orientations and, concentrated 
enough to maximise the number of particles per image without overlap. Vitreous ice 
thickness is an important variable to control, as thick ice lowers SNR. Obviously, it 
must not exceed the mean free path of electrons at the energies used for cryo-EM 
(Figure 7) (Angert et al., 1996; Russo and Passmore, 2016).  Factors affecting the 
quality of a grid are: (i) the grid type, a variety of hole sizes and substrates are 
available; (ii) the duration and plasma used for glow discharging grids in order to 
render them more hydrophilic and (iii) blotting duration and force, all three of which 
determine ice thickness and particle distribution. All these factors must be optimised 
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empirically and devices for glow discharging and plunge freezing have been 
developed to facilitate and make the optimisation of these parameters more 
reproducible  (Passmore and Russo, 2016; Thompson et al., 2016; Drulyte et al., 
2018).  
Once the sample and grid preparation have been optimised, collection of a 
data set large enough for single particle reconstruction to a resolution where atomic 
details are visible, can be done. Data collection for such purposes is typically done 
with 300 keV microscopes equipped with direct electron detectors, although 200 keV 
microscopes have also been shown to be effective for collecting data that can lead 
to  near atomic resolution structures (Herzik et al., 2018a; Thompson et al., 2019). 
The optimal dose rate used for the data collection depends on the detector being 
used, as each detector has a dose rate at which detective quantum efficiency is 
maximal (McMullan et al., 2016). Current direct electron detectors (DDE) can be 
operated in two modes, a faster (1.5 – 5x faster) integrating mode, where signal is 
summed over the pixels of the detector and a slower counting mode, where each 
incident electron is detected with pixel or sub-pixel accuracy, giving an enhanced 
contrast. The choice of detector mode is dictated by the size of the particle, 
specimens >400 kDa can be collected in integrating mode, while smaller particles 
benefit from the enhanced contrast of the counting mode (Thompson et al., 2019). 
It is also now typical to record micrograph “movies” which are useful for correcting 
beam induced motion in the specimen improving the SNR of the final micrographs 
(Campbell et al., 2012; Li et al., 2013). Another consideration is whether to use a VPP 
if available, generally useful for small particles <100 kDa although sub-nanometre 
structures have been reported for data collected without VPP for particles of proteins 
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as small as 50 kDa (Herzik et al., 2018b). Typically micrograph movies in a data set 
are collected with a range of defocus values, to enhance phase contrast and 
adequately sample the reciprocal space (Zhu et al., 1997). VPP allows for collection 
of micrographs at values closer to focus by shifting the phase of the transmitted 
beam relative to the scattered beam, enhancing phase contrast (Danev and 
Baumeister, 2016; Danev et al., 2017). Once set up data collection proceeds 
automatically usually for at least 24 hrs or several days, depending on the 
requirements of the specimen. Some of the processing can be done as the data is 
collected, informing the data collection process (Thompson et al., 2019). 
  
Data processing and single particle reconstruction in cryo-EM.  
Cryo-EM data sets can range from hundreds to thousands of DED micrograph 
movies, depending on the sample in question and the time available for data 
collection. The individual frames of these movies often have a low SNR owing to the 
low doses typically used for data collection and imaging aberrations of the 
microscope itself. The first steps in the processing of a data set, also referred to as 
pre-processing, increases the SNR by averaging the frames of the movies and by 
correcting for the effects of imaging aberrations on the micrographs as described by 
the contrast transfer function (CTF). Other sources of signal degradation are 
addressed in the pre-processing are, the effect of movement of the specimen 
induced by the electron beam and, radiation damage. Programs like MotionCor, can 
align movie frames and produce average micrographs where the contribution of each 
frame to the average is weighted by the amount of radiation damage in it (Ripstein 
 42 
and Rubinstein, 2016; Zheng et al., 2017). Given the voltage and spherical aberration 
of the microscope, the defocus can be estimated and CTF correction for the 
micrograph movie frames or aligned movies can be performed using programs like 
Gctf and CTFFIND (Rohou and Grigorieff, 2015; Zhang, 2016).  
After pre-processing, particle co-ordinates can be defined by input from the 
user (manual picking), automatically (auto-picking) or by a compromise between the 
two (Zhu et al., 2004; Vargas et al., 2013). There are various cryo-EM processing 
packages such as RELION, XMIPP and EMAN2, which have particle picking modules 
that differ in their implementation and often the choice of program is for subjective 
reasons (Scheres, 2012b; de la Rosa-Trevín et al., 2013; Ludtke, 2016; Zivanov et al., 
2018). User input provides an opportunity for introducing bias into the processing 
by, for example by favoring some orientations over others in manual picking, 
providing biased references for some methods of auto-picking or by using 
parameters that lead to picking of high resolution noise matching the references 
(Henderson, 2013). Low pass filtering micrographs and particle references or using 
reference free auto-picking followed by visual inspection of picked particles are some 
strategies to reduce bias. Once defined, particle co-ordinates are then used to 
extract, as individual images, the particles allowing for further processing by 2D 
classification. 2D classification involves the alignment of particles in order to 
determine which particles are projections of the specimen in the same orientation, 
forming an ideal 2D class, then averaging the images in the same class to boost the 
signal while reducing signal independent noise. Alignment algorithms maximize 
cross-correlation between particles in a class or use a Bayesian approach where each 
particle makes a weighted contribution to each class average. In both cases this done 
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iteratively to exploit the increase in SNR with each iteration, as the outputs from the 
last iteration are used as inputs for the next iteration. The Bayesian approach is the 
same as a the cross-correlation approach in the ideal noise free case but better 
accounts for the typical cryo-EM case of low SNR (Scheres, 2012a, 2012c). 
Classification can be reference free or done by matching projections in the particle 
set to projections computed from a model (Frank, 2006). Reference based 2D 
classification has the risk of introducing model bias and requires a suitable reference 
be provided. 2D class averages are useful for distinguishing particles of the 
macromolecule of interest from contaminants such as crystalline ice or carbon 
support, and incomplete or damaged molecules from intact ones, allowing for the 
selection of a homogenous particle set for further image processing (Scheres, 2016). 
Heterogeneity in the particle set can also be addressed using classification in 3D. For 
the 3D reconstruction using iterative methods such as those implemented in the 
popular RELION program, an initial 3D model is required for 3D classification and for 
3D auto-refinement. This initial model can be a crystal structure or better, to avoid 
model bias, one generated from the data itself as can be done using programs such 
PRIME, cryoSPARC and RELION (Elmlund et al., 2013; Punjani et al., 2017; Zivanov et 
al., 2018). 
Several rounds of 2D classification, 3D classification and 3D auto-refinement 
may be necessary before achieving the highest possible resolution from the data, 
particularly when dealing  with large and or heterogenous data sets (Scheres, 2016). 
Despite the premise of single particle reconstruction as described so far, 
conformational heterogeneity is frequently encountered sometimes at scales that 
are not obvious in 2D and 3D classification but limit the final resolution and quality 
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of the final 3D reconstruction. As a result, other tools have been developed for 
addressing heterogeneity for the purpose of not only improving the quality of the 
reconstruction but also informing the structure function relationship of the 
biomolecule under study. Particle subtraction, were a binary mask is used to 
generate 2D projections from the data that have density within that mask subtracted, 
is useful for 3D reconstructions where flexible regions limit the accuracy of image 
alignment and the final reconstruction (Bai et al., 2015). Another approach useful for 
addressing molecular flexibility is multibody 3D auto-refinement, where parts of the 
particle that are presumed to move as rigid bodies with respect each other, are 
separately and iterative refined (Nakane et al., 2018). Principle component analysis 
of the variation in the particle set allows for the visualization of molecular motions 
that may be key to understating the function of the biomolecule and through 
quantitative analysis of this variation, the energy landscape of these motions can be 
inferred (Haselbach et al., 2018).  
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Figure 8 - Negative stain cryo-EM structure of LAT2-CD98hc. Detergent solubilized and LAT2-CD98hc 
was visualized by negative stain cryo-EM and the resultant 2D projection used for single particle 
reconstruction of the protein detergent complex structure to 21 Å. The crystal structure of CD98hc, 
blue and red ribbon on the left and spheres on the right, was docked into the smaller lobe of the EM 
map with the C terminus close to the larger lobe. The scale bar shown is 50 Å. Image was adapted 
from Meury et al., 2014. 
Negative stain single particle reconstruction of LAT2-CD98hc and insights into 
quaternary structure of heterodimer. 
L-type neutral amino acid transporter 2/SLC7A8 (LAT2) is paralogue of LAT1 
sharing 52% sequence identity with it. As stated previously LAT2 forms a covalently 
linked heterodimer with CD98hc of 124 kDa. LAT2 and LAT1 have overlapping 
substrate affinities, transporting large hydrophobic L amino acids such as tryptophan 
and phenylalanine. LAT2, in addition, has a higher affinity for more hydrophilic 
substrates such as glutamine, cysteine and serine (Meier et al., 2002). Transport by 
LAT2 is also sodium and pH independent and it is predicted to function as an 
antiporter by the alternative access mechanism (Figure 3). LAT2-CD98hc is 
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expressed, in order of descending magnitude in the kidney, placenta, brain, liver and 
spleen (Pineda et al., 1999).  
The 21 Å structure of LAT2-CD98hc is at present the only reported structure 
of a heteromeric amino acid transporter (Figure 8). It was determined using single 
particle reconstruction from negative stain TEM micrographs of the detergent 
solubilised complex (Rosell et al., 2014). The reconstruction revealed a bilobate 
structure, with the smaller lobe tilted relative to the large lobe. Due to the low 
resolution, features of the complex, such as which part of the reconstruction 
corresponded to LAT2 and which to CD98hc, were not obvious so nanogold labelling 
of LAT2 via a his6 tag on the protein allowed for localisation of the LAT2 in the larger 
lobe of the reconstruction (Meury et al., 2014). It was suggested that the complex 
was not only bound to detergent but lipids as well because of the size of the large 
lobe in EM map and molecular weight of the complex by size exclusion being 406 kDa 
(Meury et al., 2014; Rosell et al., 2014).  The crystal structure of the ectodomain of 
CD98hc docked well into the smaller lobe. The lack of internal structure in the EM 
map did not allow for docking of a LAT2 model (Figure 8). This is consistent with 
negative stain cryo-EM, since the heavy metal stain used and visualized in the 2D 
projections is on the exposed surfaces of the biomolecule (Brenner and Horne, 1959; 
Ohi et al., 2004; Thompson et al., 2016). In order to explore the interaction of LAT2 
and CD98hc, Rosell et al. combined in silico docking of the CD98hc crystal structure 
and a homology model of LAT2 with mutagenesis and crosslinking experiments. An 
extensive dimer interface was proposed, where CD98hc ectodomain almost 
completely covers the extracellular face of LAT2, interacting predominantly with 
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hydrophobic residues. This extensive interaction was suggested to be the mechanism 
by which CD98hc stabilises LAT2 (Rosell et al., 2014).  
 
OBJECTIVES 
The objectives of this study were to: 
• Exploit published sequence, structural and biochemical knowledge on LeuT-
fold transporter and homologues of LAT1 to understand its structure and 
function. (Chapter 3) 
• To develop an expression system and purification protocol suitable for the 
production of LAT1-CD98hc for biochemical and structural characterisation. 
(Chapter 4) 
• Solve structure of LAT1-CD98hc by cryo-electron microscopy and relate this 
information to its function. (Chapter 5) 
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Chapter 2 – Materials and Methods 
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This chapter describes the methods used to address the objectives of this study and 
to test hypotheses reported in the literature and arising from the work reported 
here. The results of the experiments in this chapter are reported in chapters 3 – 5 
and discussed in chapter 6. 
 
Prediction of cholesterol binding/interaction sites by sequence analysis 
The amino acid sequences for human LAT1 and the Drosophila melanogaster 
dopamine transporter (dDAT) (NCBI accession numbers NP_003477.4 and 
NP_523763.2 respectively) were aligned using PROMALS3D (Pei et al., 2008) with 
default settings. The alignment was used to identify residues in cholesterol binding 
sites I & II of the dDAT that were conserved in LAT1, thus defining putative 
cholesterol binding sites in LAT1. An alignment of LAT1 orthologous was performed 
using Clustal O to determine whether the putative cholesterol binding sites are 
conserved. Orthologues were chosen from Canis lupus familiaris, Bos Taurus, Rattus 
norvegicus, Mus musculus, Gallus gallus, Danio rerio, Drosophila melanogaster, and 
Xenopus tropicalis (NCBI accession numbers XP_850176.2, NP_777038.1, 
NP_059049.1, NP_035534.2, NP_001025750.1, NP_001121830.1, NP_001245996.1, 
and NP_001135465.1 respectively). Annotation and scoring of similarity at each 
position was done in Jalview. The LAT1 sequence was also submitted to Consurf for 
conservation analysis, using default settings (Ashkenazy et al., 2016). 
The Fuzzpro package of the EMBOSS suite (Rice et al., 2000) was used to 
search the primary sequence of LAT1 for CRAC/CRAC-like motifs in manner similar to 
Listowski et al., 2015. The search patterns were defined as [LV]-X(1,5)-Y-X(1,5)-[RK], 
 50 
[RK]-X(1,5)-Y-X(1,5)-[LV], [LV]-X(1,5)-F-X(1,5)-[RK], and [RK]-X(1,5)-F-X(1,5)-[LV], 
where (1,5) is one to five amino acids and X is any amino acid. The identified motifs 
were visualized on the outward facing open model of LAT1, generated and validated 
as described below, with sites that were within the predicted membrane 
spanning/facing regions put forward as putative cholesterol interaction/binding 
sites. The membrane embedded regions of the model were predicted using the PPM 
webserver (Lomize et al., 2012). 
 
Table 1 - Top 5 hits for LAT1 templates from the HHpred server. 
 
Comparative modelling and validation of LAT1 in outward facing open and inward 
facing occluded conformations 
The sequence for LAT1 (NCBI accession number NP_003477.4) was submitted 
to the HHpred server (Soding et al., 2005), to search using default parameters, for 
homology modelling templates in the PDB. The top five outputs are shown in Table 
1, and further information from the PDB and literature is summarized in Table 2, with 
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templates chosen highlighted in red. The apo outward facing structure of AdiC from 
Escherichia coli and the alanine bound inward facing and occluded structure of the 
APC transporter from Geobacillus Kaustophillus, PDB IDs 5J4I and 5OQT (Figure 9 & 
Figure 10) respectively, were chosen as templates for modelling LAT1 using 
MODELLER v9.19 (Webb and Sali, 2016). 10 decoys per template were generated and 
the decoy with the lowest DOPE (Discrete Optimised Protein Energy) score was 
carried forward for optimization via the ModRefiner server with a template (Xu and 
Zhang, 2011). DOPE per residue scores were calculated in MODELLER and 
Ramachandran plot analysis (Lovell et al., 2003) done for both the best MODELLER 
decoy from each template before and after submitting to the ModRefiner server (Xu 
and Zhang, 2011). Structure alignments and annotation of models was performed in 
Chimera (Pettersen et al., 2004).  
 
 
Figure 9 - Sequence alignment of LAT1 and AdiC used for homology modelling. LAT1 sequence is 
residues 41 – 456 of the canonical sequence. Alpha helices and beta strands are highlighted in red and 
green respectively as predicted by the JPred server via Jalview (Waterhouse et al., 2009). 
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Figure 10 - Sequence alignment of LAT1 and GkApcT used for homology modelling. Alpha helices and 
beta strands are highlighted in red and green respectively as predicted by the JPred server via Jalview. 
 
Table 2 - Summary of suitable homology templates for modelling LAT1. 
Protein Sequence 
identity 
with 
LAT1(%) 
Sequence 
similarity 
with 
LAT1(%) 
PDB ID Resolution 
(Å) 
Conformation 
GkApcT 23 33.4 5OQT 2.86 Inward facing 
occluded/L-Ala 
6F34 
(M321S) 
3.13 Inward facing 
occluded/L-Arg 
EcAdiC 
(dimer) 
19 25.9 5J4I 2.2 Outward facing 
open 
5J4N 2.6 Outward facing 
open/agmatine 
3L1L 3 Outward facing 
occluded/L-Arg 
3LRB 3.61 Outward facing 
open 
3NCY 3.2 Outward facing 
open 
3OB6 
(N101A) 
3 Outward facing 
open/L-Arg 
MjApcT 20 24.6 3GIA 2.32 Inward facing 
occluded apo 
3GI8 
(K158A) 
2.59 Inward facing 
occluded apo 
EcGadC 15 16.2 4DJK 3.09 Inward open 
4DJI 3.18 Inward open 
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- - - - - - - - - - - - - - - - - - - - - - - - - L F R K K P IQ L LM K E S G A K G A S L R K E L G A F D L T M
I IV G T I IG S G I F V T P T G V L K E A G S P G L A L V V W A A C G V F S IV G A L C Y A E L G T T I S K S G
L G IG A I IG T G I F V L T G V A A A E H A G P - A L V L S F I L S G L A C V F A A L C Y A E F A S T V P V S G
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N P Y R N L P L A I I I S L P IV T L V Y V L T N L A Y F T T L S T EQ M L S S E A V A V D F G N Y H L G V M SW
N P Q R D M P IG I IV S L L V C T L L Y IA V S L V L T G IV P Y EQ L N V K N P V A F A L N Y IH Q D W V A G
I IP V F V G L S C F G S V N G S L F T S S R L F F V G S R E G H L P S I L SM IH P Q L L T P V P S L V F T C V
F I S L G A IA G IT T V L L V M M Y G Q T R L F Y A I S R D G L L P K V F A R I S P T R Q V P Y V N T W L T G A
M T L L Y A F S K D I F S V IN F F S F F N W L C V A L A I IG M IW L R H R K P E L E R P IK V N L A L P V F F
A V A V F A G I IP L N K L A E L T N IG T L F A F IT V S IG V L V L R K T Q P D L K R A F R V P - F V P V V P
I L A C L F L IA V S FW K T P V E C G IG F T I I L S G L P V Y F F G V W W K N K P K W L LQ G I F S T T
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 53 
 
Docking of LAT1 ligands in LAT1 models 
The homology models of LAT1 in the apo-outward-open and inward occluded 
conformations were used for docking after refinement as described above. 3D 
structures of L-tryptophan, L-phenylalanine, L-isoleucine, L-leucine, L-valine, L-
methionine, L-histidine, L-kynurenine and triiodothyronine (T3) were downloaded 
from the human metabolome database and those of (S)-2-aminobicyclo-[2,2,1]-
heptane-2-carboxylic acid (BCH), (S)-2-amino-3-(4-((7-(3-aminophenyl)naphthalen-
1-yl)methoxy)-3,5-dichlorophenyl)propanoic acid (SKN103), (S)-2-Amino-3-(3-((2,4-
dicyano-3-(4-(2-(methylamino)-2-oxoethoxy)phenyl)benzo[4,5]imidazo[1,2-
a]pyridin-1-yl)-carbamoyl)phenyl)propanoic acid (KMH233) and  (S)-2-amino-3-(4-
((5-amino-2-phenylbenzo[d]oxa-zol-7-yl)methoxy)-3,5-dichlorophenyl) propanoic 
acid (JPH203) were generated from SMILES strings in Chem3D 15.1 (Cambridge Soft, 
Perkin Elmer) (Figure 11). The structures of all ligands were energy minimised in their 
zwitterion form before docking. Docking for each ligand was performed using 
AutoDock Vina’s web service through the UCSF chimera interface using default 
parameters. The search volume was defined to exclude the putatively membrane 
embedded surfaces of the models (Pettersen et al., 2004; Trott and Olson, 2010). The 
interaction of the best scoring docking pose were visualized and annotated using the 
Dassault Systèmes BIOVIA’s Discovery Studio Visualizer. 
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Figure 11 - 2D structures of some of the ligands docked into LAT1 models of the outward open and 
inward facing occluded conformations. 
 
Cell culture 
HEK293 and HEK293SG cells (suspension adapted; N-
acetylglucosaminyltransferase I negative cells), were cultured adherently in high 
glucose Dulbecco’s Minimal Essential Medium supplemented with 10 % v/v fetal 
Bovine Serum and incubated at 37 °C and 5 % CO2. Suspension cultures were seeded 
from adherent cultures and maintained at a density of 5 x 105 cells mL-1 in 1 and 1.5 
L spinner flasks at 180 rpm. The suspension culture medium was composed of 
minimum essential medium, Joklik modification plus 13.4 mM glucose, 24 mM 
sodium bicarbonate, 10% w/v primatone, 1% w/v pluronic and 5% v/v FBS. 
Harvesting of the suspension cultures was done every 6 days for HEK293 cells and 
every four days for the HEK293SG cells. Cell pellets were flash frozen and kept in 
cryo-storage. 
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Stable cell-line development 
To determine the optimal concentration of G418 for stable cell line 
generation, nine flasks of HEK293SG cells were seeded at density of 3.33 x 105 cells 
mL-1, each flask containing a medium with a specific concentration of the selection 
agent G418, ranging from 0 – 800 µg mL-1 in increments of 100 µg mL-1. The flasks 
were observed under the microscope daily for seven days and the growth, 
morphology and whether or not the cells were still attached, was recorded. The 
optimal concentration for selecting against G418 susceptible cells was thus 
determined. For transfection, the cells were seeded at a density of 1 x 106 per well 
and allowed to attach before transfection. For transfection, 7 µL Lipofectamine 2000 
in 250 µL optiMEM was mixed with 5 µg pcDNA3.1-LAT1-V5-His6 (Figure 12) in 250 
µL optiMEM, at room temperature before adding to the cells 24 hrs after seeding. 
Cells were transferred to a T25 culture vessel with fresh medium and 600 µg mL-1 
G418, to select for cells with stable genomic integration of the neomycin resistance 
selection marker of the plasmid. After expansion of cells to a confluent T175 flask, 
isolation of single cell derived colonies was performed by a plating a serial dilution 
from 2000 – 1.25 cells mL-1, such that there was 200 – 0.125 cells per well in a 96 well 
plate format. 48 single cell clones were expanded up to 6 well plates, at which point 
frozen stocks and lysates of each clone were prepared for screening by 
immunoblotting. A LAT1 stably overexpressing cell-line was used as positive control, 
the signal from which was used to normalize during densitometry, allowing 
comparison from blot to blot. The highest expressing clone (HEK293SG-LAT1) was 
identified and expanded up to 1 L suspension culture. Plasmid and control cell-line 
were provided by Dr David Dickens (Dickens et al., 2013). 
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Figure 12 - pcDNA3.1/V5-His TOPO expression vector used for stable cell-line development. The 
sequence for LAT1 cDNA (SLC7A5, IMAGE clone 5551612) was sub-cloned into this expression vector 
so that LAT1 protein was produced with a V5 epitope and hexa-histidine tag by Dr David Dickens 
(Dickens et al., 2013). 
Immunoblotting 
Cell lysates were prepared in RIPA lysis buffer (25 mM Tris-HCl, pH 7.6; 150 
mM NaCl, 1 % sodium deoxycholate; 1 % NP-40; 0.1 % SDS; protease inhibitor 
cocktail, Sigma) and the sample protein concentrations determined by the detergent 
compatible protein assay (Bio-Rad). Protein samples were then incubated at room 
temperature in SDS loading buffer (0.5 M Tris-Cl; 30 % v/v glycerol; 10 % v/v SDS; 
0.012 % w/v bromophenol blue) before loading on to 10 % or 12.5 % Tris-glycine SDS 
polyacrylamide gels. Dithiothreitol or β-mercaptoethanol was included in the loading 
buffer when reducing conditions were required.  20 – 40 µg total protein was loaded 
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per well for cell-lysates, 5 µL from each step, for analysis of LAT1-CD98hc 
purifications, and ColorBurst Electrophoresis marker (220 – 8 kDa, Sigma) for 
molecular weight estimation. Samples were incubated at room temperature for 30 
minutes after mixing with SDS loading buffer. Gels were run at 200 V for 1 hr and 
proteins transferred from gel to PVDF membranes by wet blotting at 100 V for 1.5 
hrs or by semi-dry blotting using Invitrogen’s iBlot. The PVDF membranes were 
blocked in 0.5 % w/v semi-skimmed milk in Tris Buffered Saline with 1 % v/v tween 
(TBST) (25 mM TrisCl, 150 mM NaCl, 20 mM KCl, pH 7.4). Incubation with anti-His6 
mouse monoclonal (1:1000; Abcam), anti-LAT1 rabbit polyclonal (1:1000) antibodies 
in TBST, was performed to probe for LAT1 or anti-CD98hc rabbit polyclonal antibody 
(1:1000) to probe for CD98hc (1:1000; H300 Santa Cruz). Visualisation was done using 
anti-mouse or anti-rabbit HRP conjugated secondary antibodies by 
chemiluminescence and film or CCD camera (GE Image Quant or Bio-Rad ChemiDoc). 
Radio ligand transport assays 
Functional assays were performed using tritium labelled levodopa (3[H]-L-
DOPA) as a tracer at 0.15 µCi/mL in transport medium (1 µM unlabelled L-DOPA; 25 
mM HEPES, pH 7.4; Hank’s Buffered Salt Solution (HBSS); 0.1 % w/v BSA). The various 
HEK293 cell-lines were seeded at a density of 1 x 106 cells/mL, 24 hours before the 
assay. Medium was aspirated off and cells washed with HBSS, before 1 mL transport 
medium, warmed to 37 °C was added. After 3 minutes, the transport medium was 
aspirated off and transport stopped by washing cells with ice cold HBSS three times. 
Cells were lysed by incubating at 37 °C in 5% w/v sodium dodecyl sulphate for 30 
minutes. The amount of radiation in the lysates was measured by liquid scintillation 
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in disintegrations per minute which were used to calculate the amount of L-DOPA 
taken up per million cells in pmoles.  
Protein purification 
HEK293-LAT1 or HEK293SG-LAT1 cell pellets were retrieved from cryo-
storage and thawed on ice in 5 mL lysis buffer per gram of wet biomass (10 % v/v 
glycerol; Dulbecco’s phosphate buffered saline, pH 7; Pierce protease inhibitor 
tablets, no EDTA). The cell suspension was lysed by TissueRuptor (Qiagen) at 
approximately 24 000 rpm for 2 minutes followed by six cycles of sonication (20 secs 
on/off). Cell nuclei and debris were removed by centrifugation between 23,500 g for 
20 minutes. The supernatant was then ultra-centrifuged at 206,000 g for 1.5 hrs to 
isolate the membrane fraction from the soluble cytosolic fraction. The membranes 
were suspended by dounce homogeniser for solubilization in TBS1 (1.5 % w/v n-
dodecyl beta maltoside (DDM); 0.32 % w/v cholesteryl hemisuccinate (CHS); 0.1 % 
w/v lauryl maltose neopentyl glycol (LMNG); 20 mM Tris-Cl; 300 mM NaCl; 10 % w/v 
glycerol, pH 8). Solubilisation was performed overnight, concomitantly with V5 
affinity gel (Biotools) incubation, 10 µL resin slurry was used for 1 mL solubilisation 
suspension. The fraction of the solubilization suspension not bound to the affinity 
gel, was removed by decanting the supernatant after centrifugation at 1500 g for 2 
minutes. Resin was then washed in SEC1 buffer (0.02 % w/v DDM; 0.0013 % w/v 
LMNG; 0.00426 % w/v CHS; 100 mM Tris-Cl; 300 mM NaCl; 10 % w/v glycerol, pH 8) 
until A280 of used wash buffer was ~ 0.2. LAT1-CD98hc was eluted by incubating the 
washed resin with 400 µg mL-1 V5 peptide for 30 minutes. Further purification was 
performed by size exclusion chromatography on a Superdex 200 10/300 column. The 
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purified protein was concentrated using a 100 kDa cut-off polyethersulfone 
centrifugal filter and the pure protein concentration calculated using the molar 
extinction co-efficient at 280 nm in water, of  164750 M-1 cm-1, calculated from the 
combined primary sequence of LAT1 and CD98hc by ExPASy ProtParam (Gill and von 
Hippel, 1989). In the final year V5 affinity gel was no longer available from Biotools 
and the Sigma version was used. Sigma’s gel had at least 10 times less of capacity of 
the Biotools gel. 
Determining optimal conditions for CD98hc deglycosylation  
LAT1-CD98hc was purified from 6 g HEK293 LAT1 stably overexpressing cells 
and separately from 6.5 g of HEK293SG stably overexpressing cells, as described 
above. After final size exclusion chromatography step, LAT1-CD98hc containing 
samples were concentrated to 1 mg ml-1 for use in deglycosylation trials. Reaction 
conditions were set up as shown in Table 3, using 10 µL volumes. Deglycosylation 
enzymes and deglycosylation buffer were purchased from New England Biolabs.  
Determining the effect of sodium aurothiomalate hydrate on the reduction of the 
inter-subunit disulphide bond of LAT1-CD98hc 
2.6 x 106 HEK293-LAT1 cells were lysed in 300 µL RIPA or protein purification 
lysis buffer. RIPA lysis buffer was supplemented with 0, 1 or 2 mM sodium 
aurothiomalate hydrate (ATM) and the purification lysis buffer with 0, 1, 2, 5, 10 or 
20 mM ATM.  The amount of protein in the lysates was determined by DC assay and 
immunoblotting for LAT1-V5-His6 was performed as described above. Densitometry 
was performed on the resulting blots using Image studio Lite 5 (LI-COR biosciences). 
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Table 3 - Experimental conditions trialed for deglycosylation of CD98hc. 
LAT1-CD98hc from HEK293 cells/PNGase F 
 Enzyme/Incubation 
conditions 
Buffer 
1    500 units PNGase/27 °C/ 2 
hrs 
Purification buffer 
2 500 units/PNGase/37 °C/1 hr X1 glycoprotein denaturing buffer/X1 glyco2 
buffer/0.7 % NP40 
3 0 units PNGase/27 °C/2hrs Purification buffer 
LAT1-CD98hc from HEK293SG cells/EndoH 
1 0 units EndoH/4 °C 
/overnight 
X1 glycobuffer 3/X1 glycoprotein denaturing 
buffer 
2 1000 units EndoH/ 4 °C/ 
overnight 
X1 glycobuffer3 
3 1000 units EndoH/ 4 °C/ 
overnight 
X1 glycobuffer 3/X1 glycoprotein denaturing 
buffer 
4 1000 units EndoH/ 27 °C/ 
2hrs 
X1 glycobuffer 3/X1 glycoprotein denaturing 
buffer 
5 1000 units EndoH/ 27 °C/ 
2hrs 
X1 glycobuffer3 
6 1000 units EndoH/37 °C/1 
hrs 
X1 glycobuffer 3/X1 glycoprotein denaturing 
buffer 
7 1000 units EndoH/37 °C/1 
hrs 
X1 glycobuffer3 
8 2000 units EndoH/27 °C/6 
hrs 
X1 glycobuffer 3/X1 glycoprotein denaturing 
buffer 
9 2000 units EndoH/27 °C/6 
hrs 
Purification buffer 
10 2000 units EndoH/27 °C/6 
hrs 
X1 glycobuffer 3/X1 glycoprotein denaturing 
buffer 
11 2000 units EndoH/27 °C/6 
hrs 
Purification buffer 
12 4000 units EndoH/37 °C/6 
hrs 
X1 glycobuffer 3/X1 glycoprotein denaturing 
buffer 
13 4000 units EndoH/37 °C/6 
hrs 
Purification buffer 
 
The fraction of LAT1 in monomeric form was calculated by dividing the signal 
below the 45 kDa molecular weight marker by the sum of the signal below 45 kDa 
and above 100 kDa.  
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Optimisation of detergent concentration, detergent to protein ratio and DDM to CHS 
ratio in membrane solubilisation stage of protein purification 
Membranes were prepared from HEK293SG-LAT1 cells as described above, 
with the addition of 1 mM ATM to the lysis buffer, then suspend in solubilisation 
buffers with the detergent concentrations shown in Table 4. For each of experimental 
condition, 407 mg of HEK293SG-LAT1 membranes were used.  The detergent to 
protein ratio was varied by keeping constant the concentration of detergent at 0.9% 
w/v DDM, 0.06% w/v LMNG, 0.19% w/v CHS, while adjusting the solubilisation 
volume as required.  To vary the DDM: CHS ratio as shown in Table 4. DDM and LMNG 
concentrations were kept constant at 0.9% w/v and 0.06% w/v respectively. Samples 
were agitated at 4 °C with 96 µL anti-V5 affinity gel overnight. LAT1-CD98hc was 
eluted from the resin using V5 peptide and analysed on a superdex200 10/300 GL 
size exclusion column.  
Optimisation of size-exclusion buffer for protein purification 
Cell membranes were isolated from HEK293SG-LAT1 cells as described above 
but in the presence of 1 mM ATM and solubilised in the modified TBS1 (0.9% w/v 
DDM, 0.06% w/v LMNG, 0.19% w/v CHS; 20 mM Tris-Cl; 300 mM NaCl; 10 % w/v 
glycerol, pH 8). After incubation with solubilized membranes, the V5 affinity gel was 
washed with SEC1 buffer supplemented with 50 mM leucine, LAT1-CD98hc eluted 
from the gel and analysed by size exclusion chromatography in the same buffer. A 
control sample was prepared using SEC1 without leucine. The effect of leucine on the 
thermal stability of the purified HAT was determined by applying heat stress at 60 °C  
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Table 4 - Experimental conditions tested during the optimization of the solubilization 
stage of the purification. 
Effect of varying detergent concentration 
Condition Detergent concentration (% w/v) 
1 0.3 DDM, 0.02 LMNG, 0.06 CHS 
2 0.6 DDM, 0.04 LMNG, 0.13 CHS 
3 0.9 DDM, 0.06 LMNG, 0.19 CHS 
4 1.2 DDM, 0.08 LMNG, 0.26 CHS 
5 1.5 DDM, 0.1 LMNG, 0.32 CHS 
Effect of varying DDM: CHS ratio 
Condition DDM/CHS (mg/mg) 
1 1.67 
2 2.50 
3 3.33 
4 4.74 
5 9.47 
Effect of carrying detergent: protein ratio 
Condition DDM/protein (mg/mg) 
1 0.25 
2 0.5 
3 1 
4 1.5 
5 2 
 
for 10 minutes before analysing by size exclusion high pressure liquid 
chromatography (SE-HPLC) as described below but with column equilibrated with 
SEC1 buffer without leucine.   
In order to determine the optimal detergent concentration in the SEC buffer, 
LAT1-CD98hc samples were prepared in SEC buffers of increasing detergent 
concentrations, ranging from 5 – 15 times greater than SEC1 buffer detergent 
concentration, (see Table 5) while leucine concentration was kept constant at 50 mM 
This analysis was performed on the Agilent infinity 1260 high pressure liquid 
chromatography system using a BIO-SEC5 column (1000 Å³, 4.3x300 mm) 
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equilibrated with SEC2 buffer (0.1 % w/v DDM; 0.02 % w/v CHS; 0.007 % w/v LMNG; 
100 mM Tris-Cl; 300 mM NaCl; 10 % w/v glycerol, pH 8). Once the optimal detergent 
concentration had been determined another LAT1-CD98hc sample was prepared at 
the optimal concentration and the sample concentrated to 3 mg mL-1. 20 µl samples 
were taken for analysis at 0.5; 1; 1.5; 2.1 and 2.9 mg/mL and these were analysed by 
SE-HPLC. The peak area of the major peak in the chromatogram was calculated by 
integration, plotted against protein concentration, and fit to a linear regression 
passing through the origin. 
Table 5 - Experimental conditions tested during the optimization of the solubilization 
stage of the purification. 
 
 
 
Characterisation of the kinetic and thermodynamic stability of LAT1-CD98hc by SE-
HPLC 
LAT1-CD98hc was purified in SEC1 buffer and the fractions corresponding to 
the heterodimer were pooled and concentrated to 1 mg mL-1 immediately after size-
exclusion and analysed by SE-HPLC.  The SE-HPLC analysis was repeated after 3 and 
7 days to determine the stability of purified LAT1-CD98hc at 4 °C over time.  To 
determine the thermal stability of the HAT, in the presence or absence of 50 mM 
leucine in SEC1 buffer, 12 µL of purified protein at a concentration between 0.3 – 0.5 
mg mL-1 was incubated at a range of temperatures for 10 mins. Samples in SEC1 
Condition Detergent concentration (% w/v) 
1 0.1 DDM; 0.02 CHS; 0.007 LMNG 
2 0.15 DDM; 0.03 CHS;0.01 LMNG 
3 0.2 DDM; 0.04 CHS; 0.01 LMNG 
4 0.3 DDM; 0.06 CHS; 0.02 LMNG 
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buffer without leucine were heated to temperatures between 4 – 80 °C and samples 
in SEC1 buffer with leucine between 4 – 100 °C. Each sample was heated in duplicate 
or triplicate at the various temperatures. 9 µL of each sample was injected and 
analysed using the BIO-SEC5 HPLC column. The heterodimer eluted between 6.5 – 10 
minutes or 15 – 20 minutes retention time, when the samples were run at 0.2 mL 
min-1 or 0.4 mL min-1 respectively.  The peak height was normalized by dividing by 
the peak area and expressed as a fraction of the normalized peak height at 4 °C, 
which is here referred to as the relative peak intensity.  Relative peak intensity was 
plotted against temperature and the data analysed by a non-linear regression to the 
Boltzmann sigmoidal function using GraphPad Prism 5. All SE-HPLC analysis was 
performed as described above. 
 
Cryo-EM data collection and processing 
Cryo-EM data were collected at the Medical Research Council’s Laboratory of 
Molecular biology (LMB), Astbury Biostructure Laboratory (ABSL) at the University of 
Leeds and the Electron Biology Imaging Centre (eBIC) at the Diamond Light Source, 
Didcot. The quality of the data obtained with each collection was used to inform 
modifications to the sample preparation and or data collection in order to improve 
data quality. LAT1-CD98hc was purified as described above but with modification to 
the size exclusion buffer mentioned in Table 6 which also summarises the data 
collection parameters for each data set. Data processing was done in RELION versions 
2.1 and or 3 (Figure 13) (Scheres, 2012b; Zivanov et al., 2018). 
 
 65 
 
Figure 13 - General single particle cryo-EM data processing workflow. 
Interpretation of Coulomb potential maps produced by single particle reconstruction 
EM map resulting from processing of dataset 4, was tested for consistency 
with the crystal structure of the ectodomain of CD98hc (PDB ID: 2DH2) by docking 
the crystal structure into the EM map, using Chimera, after filtering the crystal 
structure to 12 Å. This was done by segmenting the map using the Segger (v1.9.4) 
tool with the map at a threshold of 0.00872 and the “Smoothing steps” parameter in 
Segger was set to 10 steps, while other options were set to default (Pintilie et al., 
2010). An apo-out open model of LAT1 was docked into the map after segmenting at 
the same threshold but “Smoothing steps” set to 3. Several segments were grouped 
to form a single segment that contained the density at the centre of the larger lobe 
of the map. The model was fit after filtering to 12 Å. After docking CD98hc 
ectodomain, residues at the interface of the heterodimer were defined loosely as the 
residues in one monomer that were 10 Å from the other (Table 7) 
 
3D auto-refinement
3D/2D classification
Manual picking, 2D classification then auto-picking
Micrograph movie processing and CTF estimation
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Table 6 - Summary of cryo-EM data collection. 
Cryo-EM data collection 
Data set Protein concentration/Buffer/Grid 
type 
Microscope and 
other data collection 
parameters 
Exploratory 
 
Aug 2016 
-  1.1 mg mL-1 
- 0.1% DDM: CHS: LMNG and 10% 
glycerol 
-  1.1 mg ml-1 
-  0.01% DDM: CHS: LMNG 
Krios LMB,300 kV, K2 
Gatan detector, 4 
micrographs per 
sample, 1.3 Å/px,  
1 
 
Feb 2017 
- 1.1 mg ml-1  
- 0.1% DDM: CHS: LMNG and 50 mM 
leucine and 10% glycerol 
- Quantifoil 2/2 
Krios 1 at ABSL, 
Leeds, 300 kV, Falcon 
III detector, 2452 
micrographs, 1.07 
Å/px, 2.25 e-per 
frame 
2 
 
Apr 2017 
- 1.1 mg mL-1  
- 0.01% DDM: CHS: LMNG, 50 mM 
leucine, and 5% glycerol 
- Quantifoil 1.2/1.3 
Krios 2 at ABSL, 
Leeds, 300 kV, K2 
Gatan detector, 3349 
micrograph movies, 
1.07 Å/px, 40 frames, 
2.18 e-/Å2 per frame 
3 
 
Aug 2017 
- 1.4 mg mL-1 
- 0.01% DDM: CHS: LMNG 50 mM 
leucine, and 5% glycerol 
- Quantifoil 1.2/1.3 
Krios (M06) at eBIC, 
300 kV, K2 Gatan 
detector, Volta phase 
plate, 1200 
micrographs movies, 
1.08 Å/px, 40 frames, 
1.4 e-/Å2 per frame  
4 
 
Sep 2017 
-   2.3 mg mL-1 
- 0.01% DDM: CHS: LMNG, and 0% 
glycerol 
-  Quantifoil 1.2/1.3 
Krios (M06) at eBIC, 
300 kV, K2 Gatan 
detector, Volta phase 
plate, 2390 
micrographs movies, 
1.06 Å/px, 40 frames, 
1.27 e-/Å2 per frame 
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Table 7 - Predicted dimer interface residues based on EM density map docking of 
CD98hc ectodomain crystal structure and apo-out open LAT1 model. 
Putative HAT interface residues 
 LAT1 CD98hc ectodomain 
Residue 
number 
73, 75, 76, 77, 78, 79, 80, 81 ,82, 164, 
225, 226, 227, 228, 229, 230, 231, 
235, 236, 237, 242, 245, 300, 301, 
302, 303, 304, 305, 306, 307, 309, 
310,314, 318 
109, 110, 111, 112, 113, 114, 115, 
427, 428, 429, 430, 431, 432, 433, 
434, 435, 436, 437, 438, 439, 455, 
456, 457, 458, 459, 460, 461, 527, 528 
 
The sequence of LAT1 and LAT2 (Uniprot ID: Q9UHI5) were aligned and the 
conservation of residues at the predicted interface of LAT2 and CD98hc ectodomain 
as well as the residues used in the crosslinking experiments performed for the 
validation of the docking of LAT2 and CD98hc ectodomain by Rosell et al., 2014 (Table 
8). Based on the sequence analysis, residues in LAT1 corresponding to those used in 
crosslinking LAT2 to CD98hc were identified and used as distance restraints for the 
docking of LAT1 and CD98hc ectodomain (PDB ID 2DH2) using the ClusPro server 
(Figure 14) (Kozakov et al., 2017).  
 
Figure 14 - Distance restraints as used in docking of LAT1 apo-out open model with CD98hc 
ectodomain crystal structure using the ClusPro server. Constraints shown in json format as used in 
docking, the outward open model of LAT1 was designated the receptor and the crystal structure of 
the ectodomain of CD98hc the ligand. 
{"required":1,"groups":[{"required":3,"restraints":
[{"type":"residue","dmax":14.3,"dmin":
3.5,"rec_chain":"A","rec_resid":"220","lig_chain":"A","lig_resid":"4
12"},{"type":"residue","dmax":10.5,"dmin":
6.3,"rec_chain":"A","rec_resid":"244","lig_chain":"A","lig_resid":"5
05"},{"type":"residue","dmax":10.5,"dmin":
6.3,"rec_chain":"A","rec_resid":"450","lig_chain":"A","lig_resid":"5
05"}]},{"required":2,"restraints":[{"type":"residue","dmax":
14.3,"dmin":
3.5,"rec_chain":"A","rec_resid":"220","lig_chain":"A","lig_resid":"1
51"},{"type":"residue","dmax":14.3,"dmin":
3.5,"rec_chain":"A","rec_resid":"325","lig_chain":"A","lig_resid":"1
51"},{"type":"residue","dmax":17.5,"dmin":
3.5,"rec_chain":"A","rec_resid":"220","lig_chain":"A","lig_resid":"1
95"},{"type":"residue","dmax":15.5,"dmin":
3.5,"rec_chain":"A","rec_resid":"324","lig_chain":"A","lig_resid":"1
95"},{"type":"residue","dmax":14.3,"dmin":
3.5,"rec_chain":"A","rec_resid":"401","lig_chain":"A","lig_resid":"4
87"}]}]}
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A two-body multibody refinement was performed using the final 3D auto-refinement 
from dataset 4. The density presumed to correspond to the ectodomain of CD98hc 
was defined as body 1 and the micellar density, body 2. Density maps for mask 
creation were created by segmenting the 12 Å map using Segger into two densities 
corresponding to each body to be refined, the map segments were Gaussian filtered 
using the “Volume Filter” tool and resampled using “vop” command onto the same 
grid as the 12 Å map. These map segments were then low pass filtered to 20 Å and 
11 Å soft edges added, in RELION 3 to create the masks used in the refinement Figure 
15. The “body.star” file was setup as described by Nakane et al., 2018. Principle 
component analysis was performed on the orientations of both bodies and the 
“eigen movies” for the first three eigen vectors were written out as a series of 
volumes in MRC format, describing the relative motions of the two bodies as 
described by these vectors. The “Volume series” tool of Chimera was used to 
visualise the movies and the “Fit in map” tool used to fit CD98hc ectodomain crystal 
structure and the outward open conformation of LAT1 in each of the volumes before 
saving each as a pdb file to be used for ensemble analysis using Chimera’s “MD 
movie” tool.  
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Table 8 - Residues predicted at the interface of LAT2 and CD98hc ectodomain from 
in silico docking and the corresponding residues in LAT1.  
Similarity scoring was done using Jalview, the greater the value of the score, the greater the 
similarity between the residues at that position. Identical residues are not assigned a score. The 
Consurf score increases with decreasing variability at that position between orthologues, indicating 
the degree of conservation. 
 
LAT2 LAT1 Similarity score LAT1 Consurf 
Score 
<10 Å in 
LAT1 EM 
structure 
K63 T73 7 9 No 
G64 G74  9 No 
E67 K77 7 1 No 
F155 F161  4 No 
P157 P167  6 Yes 
N221 F231 6 3 Yes 
F223 F233  8 Yes 
L239 Y248 7 8 No 
L297 L306  5 Yes 
N300 E309 7 1 Yes 
A301 A310  9 Yes 
A303 A312  9 No 
M384 I393 9 6 No 
Y385 F394 9 2 No 
Y390 F399 9 5 No 
F393 F402  7 No 
F440 V449 7 5 No 
L442 F451 8 5 No 
W443 W452  2 No 
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Figure 15 - Soft masks used for multibody refinement. The density map from the final 3D auto-
refinement is shown in cyan, threshold 0.00871. The mask for body 1 is shown as a mesh surface in 
red and the mask for body 2 as a mesh surface in yellow. 
 
Statistical tests 
 
Statistical tests were performed in GraphPad 7. T-tests were done for 
pairwise comparison were tested using two tailed t-tests and one-way ANOVA 
performed for multiple comparisons. Linear regression analysis was performed for 
LAT1 model docking data presented in Chapter 3. 
 
 71 
 
 
 
 
 
Chapter 3 - Sequence analysis, 
comparative modelling and docking of 
LAT1 
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Structural modelling of LAT1 has relied greatly on its bacterial homologues, this 
chapter reports novel insights into the role membrane lipids the in function of LAT1, 
gained from exploiting the published structure of a eukaryotic transporter of the 
LeuT-fold. Also, in this chapter are insights on inhibitor binding by docking of 
homology models of LAT1 in the outward facing open and inward facing occluded 
conformations.  
 
PREDICTION OF MODULATORY EFFECT AND BINDING OF CHOLESTEROL TO 
LAT1 BY SEQUENCE ANALYSIS AND COMPARATIVE MODELLING 
Crystal structures of the Drosophila melanogaster dopamine transporter 
were solved in the outward open conformation with cholesterol (site I) and CHS (site 
II) bound (Penmatsa et al., 2013; Wang et al., 2015). Residues at the interface with 
cholesterol at site I were, V34, L37, L38, I41 on transmembrane helix (TM) 1, W266, 
L270, Y273, L276, L277 on TM 5, and L347, I351 and I358 on TM 7. The interface of 
binding site II and CHS was composed of residues L73, A74, L66, Y69 on TM2, Y342, 
L346, L350, A354, F357 on TM7, and Y518 and W519 on TM11 (Penmatsa et al., 2013; 
Wang et al., 2015). Alanine was substituted for valine at position 74 in the construct 
used for crystallization. It was presumed to facilitate crystallization by 
thermodynamically stabilizing the transporter. When aligned to the sequence of 
human LAT1, 91% of the residues in binding site I were conserved, with either 
identical residues or ones of similar physicochemical properties. 70% of residues in 
binding site II were conserved (Figure 16). 
If the residues conserved between human LAT1 and dDAT, at dDAT’s 
interfaces with cholesterol and CHS in the crystal structures were required for the 
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function of LAT1, then they would also be conserved among the orthologues of LAT1. 
To test this hypothesis an alignment of 8 LAT1 orthologues from different species, 
including H. sapiens, domesticated species such as C. familarus and B. taurus and 
model organisms such as M. musculus and D. rerio was performed. Residues in both 
putative cholesterol binding sites were conserved across the orthologues suggesting 
functional relevance (Figure 17).   
 
Figure 16 - Sequence alignment of dDAT and LAT1. The sequence of human LAT1 was aligned with the 
sequence of dDAT. Residues that were observed interacting with cholesterol in the crystal structures 
of dDAT were annotated, purple and red for binding sites I and II respectively. Annotation and 
similarity scoring were done using Jalview. Image adapted from Dickens et al., 2017. 
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Figure 17 - Sequence alignment of LAT1 orthologues. LAT1 sequences from 7 different organisms were 
aligned with the human sequence and residues of the putative cholesterol binding sites were 
annotated, purples and red respectively for site I and II respectively. Annotation and similarity scoring 
were done using Jalview. Image adapted from Dickens et al., 2017. 
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Another question was whether these conserved residues were located in 
LAT1 in a manner similar to that of dDAT, forming similar putative binding sites for 
cholesterol. To address this, 10 homology models per template of LAT1 were 
generated using MODELLER based on sequence alignments to and the structures of 
E. coli AdiC in the apo outward facing conformation and the alanine bound inward 
facing and occluded structure of the APC transporter from G. Kaustophillus, PDB IDs 
5J4I and 5OQT respectively (Figure 9; Figure 10). The model with lowest overall DOPE 
(Discrete Optimized Protein Energy) score was then further improved by ModRefiner. 
The DOPE score is statistical potential derived from experimental structures 
deposited in the PDB, it is a measure of how close to the native fold a predicted 
structure is, the lower the score the closer to the native fold (Shen and Sali, 2006). 
ModRefiner optimises the global fold of predicted structures by subjecting them to 
an atomic level energy minimization, and as a result the global DOPE score and 
stereochemistry of the outward facing open and inward facing occluded 
conformations were improved (Table 9) (Xu and Zhang, 2011). The local quality of 
the models was assessed by plotting DOPE per residue score or DOPE score profile, 
smoothed over a 15 residues window, against the alignment position. Both the best 
models of outward facing and occluded conformation of LAT1 had DOPE score 
profiles similar to their templates, indicating the quality alignments used in the 
modelling were good. There were some regions of high DOPE score relative to the 
template, namely alignment positions 216 – 229 (A175 – I188) in the inward facing 
model and alignment positions 93 – 106 (C92 – L106), 191 – 195 (K191 – R195) in the 
outward open conformation (Figure 18). The conserved residues composing the 
proposed cholesterol binding sites, L53, V56, V60, F200, A207, L210, I211, I280, I284, 
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and L291 in site I and L86, W89, V94, V98, I279, L287, and V290 in site II, are adjacent 
to some of these high local DOPE score regions in the models of LAT1 generated 
(Figure 19) thus limiting the conclusions that could be drawn from the models 
particularly with respect to the docking of cholesterol. The models do allow for the 
inference that the proposed binding site residues are similarly organised and located 
as in dDAT (Figure 19). 
 
Figure 18 – Quality assessment of local structure prediction for LAT1 models before and after 
refinement by ModRefiner. The DOPE score profile of the outward open model is shown in a) and that 
of the inward facing conformation in b). The outward facing open conformation of LAT1 was modelled 
using EcAdiC and the inward facing occluded conformation GkApcT as templates and their DOPE score 
profiles are also given for comparison. 
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Table 9 - Global DOPE scores and dihedral angle analysis for homology modelling. 
Ramachandran plot analysis values are given as number of residues in favoured/ allowed/outlier 
regions of the Ramachandran plots. 
Outward facing open conformation 
Model DOPE score Ramachandran Plot 
Analysis (%) 
EcAdiC -64233.848  
Initial model -62046.527 94.7/3.6/1.8 
ModRefiner model -65038.004 97/2.4/0.6 
Inward facing occluded conformation 
GkApcT -73368.617  
Initial model -62435.633 94/3.6/2.4 
ModRefiner model -64841.848 95.9/2.1/1.9 
 
 
Given the similarity in fold and conservation of residues in the cholesterol 
binding site, it was reasonable to determine what effect, if any, membrane 
cholesterol had on the function of LAT1 in cells. Total cholesterol depletion protocols 
using methyl-b-cyclodextrin in HEK293 cells stably overexpressing LAT1, were 
recently established to determine the effect of cholesterol depletion on the kinetics 
of LAT1 mediated L-DOPA uptake (Dickens et al., 2017). After cholesterol depletion, 
the Vmax of LAT1 mediated transport decreased significantly (P<0.05) from 13,925 ± 
923 to 8,506 ± 684 pmoles/million cells/min. The Km however did not change 
significantly, from 200 ± 78 µM before depletion to 148 ± 22 µM after (Dickens et al., 
2017). Control experiments were setup to ensure that these observed changes were 
not due to cholesterol depletion induced changes in the localization of LAT1-CD98hc 
at the plasma membrane. Another possible explanation for the reduced activity of 
LAT1 observed in these experiments are changes in membrane fluidity, which 
cholesterol is known to regulate (Mouritsen and Zuckermann, 2004). Based on the 
structural homology shared with dDAT as explored here, the preferred hypothesis is 
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that cholesterol allosterically modulates the transporter, increasing the activity of 
the HAT without significantly changing its affinity for substrate L-DOPA. It is also 
possible that if LAT1-CD98hc interacts with cholesterol in the plasma membrane, it 
does not do so via the dDAT homologous sites noted. To explore additional sites that 
may interact, the sequence of LAT1 was searched for Cholesterol 
Recognition/Interaction Amino Acid Consensus (CRAC) and CRAC-like motifs (CARC). 
Thirty-one such motifs were identified with some overlap between many of them 
(Table 10).  Using the model of the outward open conformation of LAT1, and visual 
inspection it was suggested that 8 of the predicted CRAC/CARC motifs were plausible 
membrane cholesterol binding sites. These were neither located on intra– or 
extracellular loops nor were they in the core of the protein, where presumably 
membrane cholesterol could not access them. The putative interaction sites 
identified were located at positions 382/385 – 391, 182/185 – 191, 195 – 205/206 
and 210 – 221, in the primary sequence (Figure 20). Interestingly positions 195 – 
205/206 and 210 – 221, overlap with dDAT homologous binding site I residues A207, 
L210 and I211.  
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Figure 19 - Putative cholesterol binding sites on 3D model of LAT1. Residues in binding site I are shown 
in purple and those for site II are shown in red. a) Crystal structure of dDAT (PDB ID: 4PXF) with bound 
cholesterol molecules shown in spheres. b) Homologous residues on outward open conformation 
model of LAT1. Adapted from Dickens et al., 2017. 
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Table 10 - CRAC/CARC motifs identified in the primary sequence of LAT1. 
Potentially membrane cholesterol accessible motifs are highlighted with colours corresponding to 
those used to annotate their sequence on the out open conformation of LAT1 in Figure 20. 
 
Fuzzpro search pattern Position Sequence 
[LV]-X(1,5)-Y-X(1,5)-[RK] 385 - 391 LLYAFSK 
382 - 391 VMTLLYAFSK 
185 - 191 VNCYSVK 
182 - 191 LTAVNCYSVK 
151 - 158 VFATYLLK 
150 -158 LVFATYLLK 
[RK]-X(1,5)-Y-X(1,5)-[LV] 141 - 148 RPSSQYIV 
141 - 150 RPSSQYIVAL 
141 - 151 RPSSQYIVALV 
112 - 121 KSGGDYAYML 
112 - 123 KSGGDYAYMLEV 
[RK]-X(1,5)-F-X(1,5)-[LV] 391 - 396 KDIFSV 
348 - 352 RLFFV 
195 - 205 RVQDAFAAAKL 
195 - 206 RVQDAFAAAKLL 
158 -166 KPLFPTCPV 
[LV]-X(1,5)-F-X(1,5)-[RK] 471 - 479 VYFFGVWWK 
469 - 479 LPVYFFGVWWK 
449 - 453 VSFWK 
446 - 453 LIAVSFWK 
386 - 391 LYAFSK 
385 - 391 LLYAFSK 
349 - 355 LFFVGSR 
339 - 348 VNGSLFTSSR 
227 - 237 LDPNFSFEGTK 
214 - 221 LGFVQIGK 
213 - 221 LLGFVQIGK 
210 - 221 LIILLGFVQIGK 
196 - 204 VQDAFAAAK 
150 - 158 LVFATYLLK 
148 - 158 VALVFATYLLK 
127 - 132 LPAFLK 
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Figure 20 - Putative CRAC/CARC motifs visualized on model outward facing conformation of LAT1. 
Sequences identified by pattern searching LAT1 that are membrane embedded and thus membrane 
cholesterol accessible are highlighted on structure in blue (position 210 – 221), yellow (position 195 – 
206), green (position 181 – 191) and magenta (position 382 – 385). The red and blue lattices 
demarcate the predicted extracellular facing and intracellular facing parts of the plasma membrane, 
respectively. 
 
EXPLORING LAT1 INHIBITOR BINDING BY IN SILICO DOCKING INTO OUTWARD 
FACING AND INWARD FACING MODELS OF THE TRANSPORTER 
There have been significant efforts and successes in the development of 
potent high affinity LAT1 inhibitors as potential chemotherapeutics (Oda et al., 2010; 
Huttunen et al., 2016; Kongpracha et al., 2017; Napolitano et al., 2017b). So far, these 
efforts have been mostly based on the screening of synthetic compounds, designed 
to mimic known substrates of LAT1, through mostly cis-inhibition transport assays. 
Since the poor-quality regions of the two structural models of LAT1 are outside the 
substrate binding site of the transporter, they provided an opportunity to 
characterize, in silico, the molecular mechanisms of some of the reported inhibitors, 
(Figure 18). Two cavities corresponding presumably to the substrate binding site of 
the transporter were visible in the models (Figure 21). The cavity at the core of the 
outward facing conformation was accessible from the extracellular facing side 
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whereas in the inward facing conformation, the cavity was occluded from both the 
extracellular and intracellular sides, which is consistent with the conformations of 
the templates used in the modelling of either conformations (Kowalczyk et al., 2011; 
Jungnickel et al., 2018).  
 
 
Figure 21 - Slice through models of the outward facing open and inward facing occluded conformations 
of LAT1. The red and blue lattices demarcate the predicted extracellular facing and intracellular facing 
parts of the plasma membrane, respectively. a) The outward open conformation has a large cavity 
with two parts, demarcated by F252. b) A large central cavity is visible in the inward occluded 
conformation and is closed off from the extracellular side by several residues including F252. 
Previously reported, putative substrate binding site residues, T62 – S67, I139, 
I140, V148, F252 – G255, S342, S401, F402, and W405, were located mostly in the 
lower part of the cavity proximal to extracellular vestibule, in the model of the 
outward open conformation and in the cavity of the inward occluded conformations 
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(Figure 22b & d) (Geier et al., 2013). F252 in the model of the outward open 
conformation, was positioned to act as a gating residue, opening or occluding the 
putative substrate binding site from the extracellular space in a similar manner to 
W202 in AdiC and F231 in GkApcT, which is consistent with the observation that this 
position is conserved between LAT1, AdiC and GkApcT (Figure 22c & d) (Gao et al., 
2010; Jungnickel et al., 2018). The arrangement of these putative substrate binding 
site residues was compared by structural alignment to the experimentally validated 
in silico model of LAT1 in the outward open conformation from the Schlessinger lab 
(Chien et al., 2018). The two models had a Ca-RMSD of 0.68 Å and some differences 
in the putative binding site residues (Figure 22a & b). Worth noting was the sidechain 
of F252, which is in a different conformation in the two models, with the control 
model having the sidechain facing away from the opening of the cavity (Figure 22b). 
The inward facing occluded and outward facing open models have a higher Ca-RMSD 
of 1.37 Å and some differences in the residues of the putative substrate binding site 
particularly F252 – F255. The side chain of F252 has a similar conformation in both 
models, that is facing toward the cavity, but in the inward occluded conformation, 
the top half of TM6 is shifted more toward the opening of the cavity rendering it 
inaccessible from the extracellular side (Figure 22c & d). The Ca-RMSD of F252 – F255 
on TM6 between the inward facing occluded conformation and the outward open 
conformation is 2.40 Å, compared to 1.36 Å between the outward open model and 
the control model.  
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Figure 22 - Alignment of LAT1 homology models and their putative binding site residues. a) Aligned 
models of LAT1 in the outward facing open conformation. Control model is shown in purple and my 
model in blue. Binding site residues in each model are aligned and shown in (b). c) Aligned models of 
LAT1 in the inward facing occluded (red) and my outward facing open (red) conformations. Binding 
site residue conformations are aligned and shown in (e). 
As further validation of the models, known substrates of LAT1 as well as 
inhibitors, JPH203, SKN203 and KMH233, were docked into the putative substrate 
binding sites of the two new models and the control model (Table 11; Figure 23). 
There was an evident correlation between the predicted binding free energy/score 
from the docking of a LAT1 ligand and its molecular weight with R2 values of 0.61 
(P<0.05), 0.64 (P<0.05) and 0.44 (P<0.05) for the control, outward open and inward 
occluded models respectively (Table 11; Figure 23). For all three models the R2 was 
lowered by the inclusion T3, which appears to be an outlier. Without T3 in in the linear 
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regression, the R2 values are 0.97 (P<0.0001), 0.94 (P<0.0001) and 0.91 (P<0.0001) 
for the control, outward open and inward occluded models respectively. T3 has the 
highest molecular weight of all the ligands but not the most favourable predicted 
binding free energy. This is because T3 has three iodine atoms (Ar = 126) in its 
structure, each of which has an atomic weight (Ar) much higher than the C (Ar = 12), 
N (Ar = 14), O (Ar = 18) atoms that make up the other ligands, with the exception of 
JPH203 and SKN103 which also have Cl (Ar = 35) and methionine which has S (Ar = 32) 
(Figure 2.2). The observed correlation maybe because the higher molecular weight 
ligands, with the exception of T3, have more atoms and therefore potentially more 
interactions with LAT1, thermodynamically favouring their binding. The linear fits of 
the docking scores from both the control and out open model are similar indicating 
that the two models are of similar predictive power with regard to the predicted free 
binding energies of LAT1 ligands and thus presumably the binding modes of these 
ligands. Although following a similar trend to the out open models, the inward 
occluded model has better scores for all the ligands docked except KM233 which 
does not dock at the substrate binding site in this conformation (Table 11). Overall 
both the out open and inward occluded models of LAT1 appear sufficiently plausible 
to explore structure activity relationships between LAT1 and some of its inhibitors. 
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Table 11 - Predicted binding energies of LAT1 ligands at the putative substrate binding 
sites of homology models in the outward facing and the inward facing conformations.  
An experimentally validated model of the outward open conformation from the Schlesinger lab was 
used as a control. 
 
Predicted free energy of binding/Score (kcal mol-1) 
Ligand MW (Da) Control Outward open Inward occluded 
BCH 155.197 -5.4 -5.7 -5.8 
Histidine 155.155 -5.2 -5.2 -6.4 
Phenylalanine 165.19 -5.6 -5.6 -6.5 
Tryptophan 204.23 -6.8 -6.8 -8.0 
Leucine 131.17 -5.2 -4.4 -5.1 
Isoleucine 131.17 -4.6 -4.6 -5.5 
Methionine 149.21 -4.4 -4.0 -4.5 
Valine 117.151 -4.3 -4.2 -5.3 
Kynurenine 208.22 -6.3 -6.4 -6.8 
Triiodothyronine (T3) 650.977 -7.3 -7.5 -6.9 
JPH203 472.32 -10.6 -10.7 -12.3 
KM233 587.6 -11.2 -10.6  
SKN103 481.37 -10.7 -9.8 -12.9 
 
 
Figure 23 - Trends in molecular weight and predicted binding energy. The predicted binding 
energies/scores of 10 know substrates and 3 synthetic inhibitors to the outward open and inward 
occluded conformations of LAT1 were plotted against their molecular weight. Linear regression was 
performed and the fitted lines are shown. R2 values for regression are 0.97 (P<0.0001), 0.94 (P<0.0001) 
and 0.91 (P<0.0001) for the control, outward open and inward occluded models respectively. 
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Figure 24 - Ligand docking onto outward open model of LAT1. a) Slice through of surface of model with 
phenylalanine (green) docked at the putative binding site shown as sticks. b) Residues in the model 
interacting with phenylalanine. c) Slice through of surface of model with JPH203 (cyan) docked at the 
putative binding site shown as sticks. d) Residues in the model interacting with JPH203. e) Slice 
through of surface of model with KMH233 (green) docked at the putative binding site shown as sticks. 
f) Residues in the model interacting with KMH233. g) Slice through of surface of model with SKN103 
(purple) docked at the putative binding site shown as sticks. h) Residues in the model interacting with 
SKN103. Electrostatic attractions are shown with dashed dark orange lines, H bonds are shown with 
dashed green lines and Van der Waals (VdW) interaction with pink dashed lines. 
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Figure 25 - Inhibitor docking onto inward open model of LAT1. a) Slice through of surface of model 
with SKN103 (purple) docked at the putative binding site shown as sticks. b) Residues in the model 
interacting with SKN103. c) Slice through of surface of model with JPH203 (cyan) docked at the 
putative binding site shown as sticks. d) Residues in the model interacting with JPH203. Electrostatic 
attractions are shown with dashed dark orange lines, H bonds are shown with dashed green lines and 
VdW interaction with pink dashed lines. 
Consistent with previous reports, H-bonding between the backbone of G65, 
G67, T62 and I63 and the sidechain of S66 with the amino acid functional groups of 
the ligands of LAT1, such as phenylalanine, was predicted from the docking poses in 
both the outward open and inward occluded conformations with the exception of 
KMH233 (Figure 24; Figure 25) (Geier et al., 2013). KMH233’s amino acid moiety was 
bound to a pocket on the extracellular side of F252. It was recognised by K453, which 
was predicted to electrostatically attract the carboxyl of the amino acid via its 
positively charged side chain, and also bound by N398 and Y248 via hydrogen 
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bonding with their sidechains. KMH233 was also predicted to bind to the outward 
open conformation by hydrogen bonding with G65, S66 and N404 as well as p-p 
stacking and t-stacking with F252 (Figure 24e & f). The numerous interactions 
between KMH233 may explain why this ligand binds strongly and with specificity to 
LAT1 (Table 12) (Huttunen et al., 2016). The predictions that this ligand may interact 
strongly via electrostatic interaction and hydrogen bonding with residues in the 
extracellular vestibule, by hydrogen bonding and VdW interactions with the 
extracellular gate (F252) and residues across it, are consistent with observation that 
KM233 is not a transported ligand of LAT1.  This binding pose may preclude 
conformational change from the outward open to an occluded state thereby 
sterically hindering the movement of F252 – F255 to the inward occluded 
conformation (Huttunen et al., 2016). KMH233 is also the only inhibitor that could 
not be docked onto the inward occluded model, which suggests that it cannot bind 
to this conformation and therefore cannot be transported by LAT1.  
JPH203 and SKN103 were predicted to bind to the substrate binding site in 
both the outward open and inward occluded conformations. In addition to H bonding 
with G65 – G67 and S144, JPH203 was predicted to interact with the outward open 
conformation via p-alkyl interactions with F252 and I140 (Figure 25b). In the inward 
occluded model, SKN103 was predicted to interact with LAT1 via H bond with G55 – 
G66, F252, A253, G255, and S338 in addition to p-alkyl interactions with F400, I139, 
I140, and L349 (Figure 25d). The prediction of a more extensive H bonding network 
and VdW interactions between SKN103 and the inward occluded conformation 
compared to the outward open conformation, may explain the difference in the 
predicted free binding energies between the two models, -12.9 and -9.8 kcal mol-1 
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respectively. JPH203 also has had a higher predicted binding free energy to the 
inward occluded conformation, -12.3 kcal mol-1, than the outward open 
conformation -10.6 kcal mol-1. Of the three inhibitors considered here, JPH203, has 
highest affinity, as inferred from IC50 calculations and this may be because it binds 
and interacts more extensively with the inward occluded conformation in LAT1’s 
transport cycle (Table 12).The predicted interactions of JPH203 and SKN103  with 
LAT1, suggest similar binding affinity for the two inhibitors (Oda et al., 2010; 
Kongpracha et al., 2017). Both JPH203 and SKN103 interacted with more residues in 
the binding site than those typically involved in the interaction of LAT1 and its 
transported substrates such as phenylalanine and BCH, which may explain not only 
their higher affinity of the transporter but also leave open the question of whether 
these interactions preclude their transport either sterically or by stabilising 
intermediates in the transport cycle of LAT1.  
In the inward open model, F252 interacts with NH3+ of the amino acid of the 
substrates, including JPH203 and SKN103 by a p-cation bond (Figure 25).  This 
interaction may be important to the recognition of a LAT1 substrate, stabilizing the 
inward occluded conformation as well as facilitating transport. The distance (<6 Å) 
and geometry between the amino group of the substrate alanine and the face of the 
benzene side chain of the extracellular gating residue F231 in the GkApcT structure, 
on which the inward occluded model was based, allows for such a p-cation 
interaction (Jungnickel et al., 2018). This supports the hypothesis that this interaction 
is important for the formation of this conformation and thus substrate transport. 
When the corresponding gating residue in the predicted model of LAT2, F242 was 
mutated to the valine, transport activity decreased while mutation to tryptophan at 
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the same position results in increased activity relative to the wild type, suggesting a 
role for the aromatic nature of the residue in this gating position (Hinz et al., 2015).  
Interestingly p-p stacking was observed between phenylalanine and F252 in the 
outward open conformation, an interaction that has been suggested to explain the 
apparent preference for aromatic side chains over alkyl ones in LAT1 substrates, a 
preference also consistent with the trend observed in the predicted binding free 
energies of the substrates (Ylikangas et al., 2013; Chien et al., 2018). 
 
Table 12 - LAT1 transport inhibitors and their IC50s 
LAT1 inhibitor IC50 (µM) (transport inhibition) 
KMH233 18.2 ± 1.2  (Huttunen et al., 2016) 
SKN203 1.98 ± 1.07 (Kongpracha et al., 2017) 
JPH203 0.14  (Oda et al., 2010) 
 
CONCLUSION 
 As of December, 2017, there were twenty-three solute carrier structures 
deposited in the Protein Data Bank, less than half of which are from mammalian 
organisms. Due to this small number of experimental structures, for high value 
pharmacological targets such as LAT1 where structural information is essential, much 
of the structure function work has relied on homology models (Reviewed by Bai, 
Moraes and Reithmeier, 2017; Singh and Ecker, 2018). The bacterial homologues of 
LAT1, EcAdiC and MjApcT, have been the most exploited for the purposes of 
homology modelling of the transporter usually in the outward open conformation, 
yielding much information about the structure-activity relationship of LAT1 and 
leading to development of potent inhibitors (Geier et al., 2013; Augustyn et al., 2016; 
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Zur et al., 2016; Napolitano et al., 2017b; Chien et al., 2018; Palazzolo et al., 2018). 
Conversely, knowledge gained from other crystal structures of LeuT-fold transporters 
such as the dDAT and SERT has been under-utilized for the understanding of LAT1 
function. The activities of both the dDAT and SERT transporters have been shown to 
be modulated by membrane cholesterol and when solved, their structures revealed 
cholesterol binding sites (Penmatsa et al., 2013, 2015; Coleman et al., 2016). A 
combination of sequence analysis and structure prediction supported the hypothesis 
that LAT1 interacts with and is modulated by membrane cholesterol possibly through 
sites homologous to dDAT and or through CRAC/CARC motifs in the transporter’s 
transmembrane domains. LAT1 mediated uptake of L-DOPA has indeed been shown 
to be modulated by membrane cholesterol, but whether this is by direct interaction 
remains undetermined (Dickens et al., 2017). The interaction of cholesterol and 
cholesterol hemisuccinate with dDAT stabilized the outward open conformation, 
reducing conformational heterogeneity; something that could facilitate structural 
study of LAT1.  
 In the case of dDAT and SERT, high affinity inhibitors were also key to 
stabilizing the transporters in a single conformation making them more amenable to 
crystallization (Penmatsa et al., 2013, 2015; Coleman et al., 2016). Several inhibitors 
of LAT1 have been reported, namely KMH233, SKN103 and JPH203, and the binding 
mode of these has been here explored by docking to predictive models of LAT1 in the 
outward open and inward occluded conformation (Oda et al., 2010; Huttunen et al., 
2016; Kongpracha et al., 2017). All three inhibitors were found in the substrate 
binding site of the outward open conformation, in a manner similar to transported 
substrates with exception of KM233. KM233 was also the only inhibitor that did not 
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dock to the substrate binding site of the inward occluded conformation and because 
of its interaction with the extracellular gate residue, F252, and residues across it in 
the substrate binding site, the inhibitor probably prevents formation of the inward 
occluded conformation and thus cannot be transported. JPH203 and SKN103 docked 
to the inward occluded conformation as substrates but had predicted binding free 
energies higher than those of transportable substrates, leaving it an open question 
whether they are transported by LAT1. As far as stabilising a particular conformation 
for the purpose of structural characterisation, KM233 seems like the best candidate 
between the three inhibitors explored here, although it has lowest affinity of the 
three as inferred from IC50 calculations.  
Here I have elaborated upon several hypotheses that are open to 
experimental testing. Namely, LAT1 interacts with cholesterol via specific residues; 
the inhibitors of LAT1 studied here are most likely competitive inhibitors; KM233 is 
not a transportable ligand of LAT1; and JPH203 and SKN103 are most likely substrates 
of LAT1. The first one can be tested by solving the structure of LAT1 in the presence 
of cholesterol, but solving the structure of LAT1 has so far remained elusive. An 
alternative approach would be a combination of the cholesterol depletion followed 
uptake assay experiments used by Dickens et al., 2017 and mutagenesis of the 
proposed cholesterol binding site residues. Whether the inhibitors of LAT1 are 
competitive inhibitors or not, can be inferred by determining the effect of the 
inhibitors on the Vmax and Km of LAT1 mediated transport, a competitive inhibitor 
should alter the Vmax but not Km of the transporter. Trans-stimulation assays in cells 
or proteoliposomes would be useful for determining whether these inhibitors are 
transported substrates or not. 
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Chapter 4 - Overexpression, purification 
and biophysical characterisation of LAT1-
CD98hc 
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This chapter reports development of an expression system and purification protocol 
for the production of LAT1-CD98hc. Biochemical characterisation of the thermal and 
kinetic stability of the complex in detergent and the impact of ligand binding on these 
is also explored.   
 
LAT1 OVEREXPRESSION AND STABLE CELL-LINE DEVELOPMENT 
The suspension adapted and N-acetylglucosaminyltransferase I deficient, 
HEK293SG expression system was chosen for its capacity for natively folded, 
mammalian membrane protein over-expression with simplified endoglycosylase 
sensitive glycosylation (Reeves et al., 2002; Chaudhary et al., 2012; Goehring et al., 
2014). Cells were transfected with a pcDNA3.1 plasmid for LAT1-V5-His6 fusion 
protein expression. G418 selection was used to isolate a heterogeneous pool of cells 
with stably integrated expression vector in their genomes.  Forty-eight clones were 
isolated as described in the Methods Section and screened by immunoblotting for 
the LAT1-V5-His6 fusion protein. Once identified, the highest expressing clone was 
expanded up and assayed for the function of the exogenous LAT1. A HEK293-LAT1 
cell-line was used as a positive control and HEK293SG cells as a control for 
endogenous transporter meditated up take. HEK293SG-LAT1 accumulated more L-
DOPA than the HEK293SG control (48.0 ± 12.1 vs 12.7 ± 3.8 pmol/1 x 106 cells; p value 
<0.01) and HEK293-LAT1 cells (48.0 ± 12.1 vs 31.9 ± 5.3 pmol/1 x 106 cells; p value 
<0.01), which expressed less of the fusion protein as determined by immunoblotting 
(Figure 26). This result was indicative of functional LAT1-V5-His6 in the HEK293SG cell-
line. The smeared signal of CD98hc from the HEK293-LAT1 cell-line, compared with 
the 6 discrete bands from the HEK293SG-LAT1 cell-line in Figure 26a, is consistent 
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with data in the literature (Reeves et al., 2002), showing that the heavy chain of the 
HAT is glycosylated and that HEK293SG cells produce simplified glycosylation.  
 
Figure 26 - Stable over-expression of functional LAT1-CD98hc in HEK293SG cells. (a) Immunoblotting 
following SDS-PAGE in reducing conditions was used to detect LAT1-V5-His6 in the highest expressing 
HEK293SG single cell derived clone.  CD98hc was up regulated in response to LAT1 overexpression 
and displayed a simplified glycosylation pattern in HEK293SG-LAT1 relative to HEK293-LAT1. (b) The 
function of the HAT was assayed by L-DOPA accumulation in the various cell-lines. Both HEK293-LAT1 
and HEK293SG-LAT1 cell lines accumulated more L-DOPA in three minutes than the control cell-line, 
consistent with LAT1 overexpression (error bars are SD; n = 3). 
 
STABILIZATION AND PURIFICATION OF LAT1-CD98hc 
Once the expression and function of LAT1-V5-His6 had been established, the 
HEK293SG-LAT1 cells were grown in 1.0 and 1.5 L suspension culture flasks. An 
immunoaffinity purification workflow developed using the HEK293-LAT1 cell-line 
(Figure 27a), was applied for purification of the HAT from the new cell-line. The work 
flow was assessed at each step by immunoblotting (Figure 27b) and modified as 
necessary to optimize the process as described in detail below.  The first lysis step 
was modified by the introduction of ATM to inhibit the reduction of the disulphide 
bond that covalently attaches the light chain to the heavy chain, stabilizing the 
heteromeric complex.  Small scale experiments showed that including 1 mM ATM, 
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reduced the proportion of total LAT1 in a monomeric state on non-reducing SDS-
PAGE, from 42% to 9%. Concentrations greater than 1 mM resulted in no further 
reduction in the proportion of HAT in a monomeric state (Figure 28).  
 
Figure 27 - Immuno-affinity purification of LAT1-CD98hc. (a) The HAT was purified by immunoaffinity 
precipitation as illustrated by this work flow. The peak eluted at 10.5 mL was analysed by 
immunoblotting for LAT1-V5-His6 and the degree of purity by SDS-PAGE in non-reducing conditions 
followed by Coomassie staining. (b) The efficiency of each step of the purification was assessed by 
immunoblotting for LAT1-V5-His6. Molecular weights are in kDa. 
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Figure 28 - The effect of ATM in lysis buffer on reduction of the HAT disulphide bond. (a) Lysates 
prepared in various concentrations of ATM were analysed by immunoblotting for LAT1-V5-His6 in non-
reducing conditions.  (b) The fraction of LAT1 in monomeric state after non-reducing SDS-PAGE was 
calculated by densitometry. 
 
DEGLYCOSYLATION OF PURIFIED LAT1-CD98hc 
Complex glycosylation is often a source of biochemical heterogeneity which 
can hinder structural study but sometimes removing it destabilises the protein of 
interest (Nettleship, 2012). With this in mind, the glycosylation state of CD98hc was 
characterised and a deglycosylation strategy developed.  Immunoblotting of CD98hc 
co-purified with LAT1 from HEK293 showed a diffuse band between 60 - 100 kDa; 
this band has been replaced by at least 6 distinct bands (Figure 29) after treatment 
of the purified protein with PNGase F, an amidase that is most effective for removing 
almost all N-linked oligosaccharides from glycoproteins, at 37 °C and 27 °C for 1 hr 
and 2 hrs respectively. The higher molecular weight bands were missing or fainter in 
the sample incubated at 37 °C compared to 27 °C. LAT1-CD98hc purified from 
HEK293SG cells, when run on SDS-PAGE and Coomassie stained, had a similar pattern 
of 6 distinct bands between 60 – 100 kDa and a band less than 45kDa consistent with 
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the light chain of the HAT (Figure 29b). When LAT1-CD98hc purified from HEK293SG 
cells was incubated with EndoH enzyme, at 4 °C for 16 hrs or at 27 or 37 °C for less 
than 6 hrs there was some apparent deglycosylation when compared to the control 
sample, the largest molecular weight band disappeared and two new bands less than 
60 kDa appeared. The density of the 5th largest band appeared reduced as well 
(Figure 29c). Incubation for 6 hrs at 27 °C or 37 °C reduces the number of bands 
visible to two that are less than 60 kDa, and are absent from the untreated control 
sample (Figure 29c). The apparently similar efficiency of deglycosylation between the 
native and denatured samples is consistent with the glycans being solvent accessible 
(Figure 29c; Figure 5). 
 
Figure 29 - Analysis of CD98hc glycosylation using purified LAT1-CD98hc and deglycosylase enzymes, 
PNGase F and Endo H. (a) Immunoblot with anti-CD98hc polyclonal antibody of LAT1-CD98hc purified 
from HEK293 cells and treated with 500 units PNGase F for 1 or 2 hrs at 37 °C and 27 °C respectively. 
(b) LAT1-CD98hc purified from HEK293SG-LAT1 cells, analysed by SDS-PAGE in reducing conditions 
and Coomassie stained. This sample was used in the EndoH experiment and served as a negative 
control. Molecular weights (MWM) are given in kDa (c) Immunoblots with anti-CD98hc antibody in 
reducing conditions of LAT1-CD98hc purified from HEK293SG cells, after incubation with 2000 or 
4000(*) units EndoH in the conditions indicated.  
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OPTIMISATION OF LAT1-CD98hc PURIFICATION BY IMMUNOAFFINITY 
PRECIPITATION 
Lipid membrane solubilization begins at detergent concentrations in excess 
of the critical micelle concentration (Le Maire et al., 2000).  Optimization is necessary 
to achieve  efficient of solubilization, without compromising stability of the protein 
detergent complex of interest (Privé, 2007). As a starting point, the conditions 
reported by Meury et al., 2014 for the solubilisation of LAT2-CD98hc from P. pastoris, 
were used for HEK293SG-LAT1 cell membranes. Membranes were prepared and 
solubilised overnight in a mixture of DDM, LMNG and CHS micelles (5:1 DDM to CHS 
and 3:1 CHS to LMNG) at a DDM concentration of 1.5 % w/v. Given that DDM has a 
low CMC, 0.0009% w/v, 1.5 % w/v is well in excess of the CMC and is 0.5 % more than 
is typical used for membrane solubilization therefore the optimal detergent 
concentration was sought by solubilising cell membranes and immuno-precipitating 
LAT1-CD98hc in decreasing concentrations of detergent, from 0.3 – 1.5 w/v. The 
analysis of the efficiency of solubilisation was performed by size-exclusion 
chromatography as described in Chapter 2 (Figure 30a). The peak height between 
10.3 - 10.5 mL retention volume, corresponding to pure HAT dimer, increased from 
30.15 to 69.65 mAU, as the DDM concentration was lowered from 1.5 to 0.9 % w/v, 
respectively. Below DDM concentration 0.9 % w/v, the peak height decreased as 
detergent concentration decreased. Based on this result, subsequent solubilization 
and purification experiments were performed at 0.9 % w/v DDM.  
Another parameter selected for optimization was the DDM:CHS ratio. CHS 
appears to be important for the purification LAT1-CD98hc (Figure 30b). DDM:CHS 
ratios of 3.3 and greater, had no effect on the peak height between 10.3 - 10.5 mL 
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retention volume, compared to the control ratio of 4.74. Ratios less than 3.3 resulted 
in reduced peak height (Figure 30c). Based on the results of this experiment the 
DDM:CHS ratio was maintained at 4.74. 
 
Figure 30 - Optimization of membrane solubilization step of LAT1-CD98hc purification. Detergent 
concentration (a), DDM:CHS (c) and detergent to protein ratio (d) were varied as described in the 
methods and the effects of LAT1-CD98hc analysed by size exclusion chromatography. The 
chromatogram of the chosen as being to be optimal is illustrated by the unbroken line in each of 
graph.  (b) The size exclusion chromatography of LAT1-CD98hc purified in the presence or absence of 
CHS in the membrane solubilisation and SEC1 buffer. 
The final solubilisation  parameter selected  for optimisation was the DDM: 
Protein ratio. This was done by keeping the detergent concentration constant at 0.9 
% DDM while varying the solubilisation volume. A ratio of 0.5, which was also the 
control ratio, was found to be the optimal condition for LAT1-CD98hc purifcation 
(Figure 30d). 
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OPTIMIZATION OF SIZE-EXCLUSION BUFFER FOR PURIFICATION 
The initial buffer condition used for washing V5 affinity resin, elution of LAT1-
CD98hc and preparative size exclusion chromatography was refered to as SEC1 buffer 
(0.02 % w/v DDM; 0.0013 % w/v LMNG; 0.00426 % w/v CHS; 100 mM Tris-Cl; 300 mM 
NaCl; 10 % w/v glycerol; pH 8). It yielded 100 µg from 1 L of suspension culture. The 
SEC1 DDM concentration, double the CMC, was chosen in order to keep the HAT 
stable in solution by preventing disintegration of the protein-detergent complex. 
LAT1-CD98hc was kinetically stable in the buffer for 7 days at 4 °C with no detectable 
aggregation or denaturation by size exclusion high performance liquid 
chromatography (SE-HPLC) (Figure 33a). The Tm of the HAT in SEC1 buffer was 47 °C 
(Figure 33c).  Optimisation was undertaken in an attempt to improve the yield per 
litre as well as the thermal and conformational stability of LAT1-CD98hc.  
Leucine was chosen for the determination of the effect of including ligand in 
the buffers used for protein purification. The inclusion of 50 mM leucine in the 
purification buffers resulted in a 39% increase in the peak height at 10.4 mL by size 
exclusion chromatography (Figure 31a). To determine whether this increase was due 
to increased stability of LAT1-CD98hc, samples of HAT purified in the presence and 
absence of leucine were heat stressed at 60 °C for 10mins then analysed by SE-HPLC. 
Figure 31b shows increased monodispersity in the presence of leucine and a 14% (p 
< 0.001) higher relative peak intensity in the presence of leucine, indicative of a 
thermal stabilising effect. Addition of 4 mM leucine did not have a significant effect 
on the relative peak intensity compared to no ligand control while the same 
concentration of kynurenine increased the relative peak intensity by 9% (p<0.01). 
There was no significant difference in relative peak intensity between 50 mM leucine 
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and 4 mM kynurenine. When determined, the Tm of LAT1-CD98hc was 10 °C higher 
in the presence of leucine (Figure 31). 50 mM leucine was included in all purification 
buffers from this point unless otherwise stated. 
 
 
Figure 31 - The effect of leucine on the yield and thermal stability of LAT1-CD98hc. (a) Protein 
purification was performed in the presence of 50 mM leucine at each stage of the purification. (b) The 
effect of leucine on the thermal stability of LAT1-CD98hc was determined by heating stressing, at 60 
°C for 10 minutes followed by SE-HPLC analysis. (c) The effect of the heat stress on the purified HAT, 
in the absence or presence of leucine was quantified by calculating the relative peak intensity (n = 3). 
(d) The stabilising of effect of leucine at 50 mM was compared to that at 4 mM for both leucine and 
another substrate kynurenine (n=5).  
Despite the improvement in the thermal stability of the HAT heterodimer in 
the presence of leucine, a significant fraction of the HAT was present in higher 
oligomeric states so further optimization was attempted. Costa et al., 2013 reported 
similar oligomerization when detergent solubilising LAT2-CD98hc, a difficulty Meury 
et al., 2014 overcame by modifying the solubilisation conditions and introducing CHS 
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into the purification. The SEC buffer detergent concentrations employed by Meury 
et al., 2014, referred to here as SEC2 (0.1 % w/v DDM; 0.02 % w/v CHS; 0.007 % w/v 
LMNG; 100 mM Tris-Cl; 300 mM NaCl; 10 % w/v glycerol, pH 8), were chosen as the 
starting point for further optimisation of the SEC buffer. Purification using SEC2 
buffer resulted in an increased HAT yield per litre from 100 to 300 µg. LAT1-CD98hc 
was eluted in 4 different SEC buffers with increasing concentrations of detergent 
followed by SE-HPLC analysis 1, 1.5, 2 and 3 times greater than SEC2. There was 
observed a 30 % increase in relative peak intensity between condition 1 and 3 but 
only a further 3 % increase in condition 4 (Figure 32b). Although increases in peak 
intensity were observed with increasing detergent concentrations, SEC2 buffer was 
used for cryo-EM to limit background from detergent. 
 
Figure 32 - Optimization of the buffer for size-exclusion chromatography. (a) Size exclusion 
chromatogram of HAT in SEC with and without leucine (b) LAT1-CD98hc was eluted off the V5 affinity 
gel in SEC buffers of varying detergent concentrations and analysed by SE-HPLC to determine the 
optimal SEC detergent concentration. To determine the stability of the HAT at concentration between 
0 – 3 mg mL-1, 20 µL of sample in condition 2, at was analysed by SE-HPLC various protein 
concentrations and the major peak area plotted against sample concentration(c).  
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The stability of LAT1-CD98hc as its concentration increased was determined 
by analysing samples of equal volume at various concentrations by SE-HPLC (Figure 
32c). Peak area increased linearly as protein concentration increased which is 
consistent with a sample stable independent of concentration (Figure 32d). 
 
 
Figure 33 - Characterization of LAT1-CD98hc kinetic and thermal stability by SE-HPLC. (a) Stability of 
LAT1-CD98hc at 4 °C was monitored for 7 days after purification by SE-HPLC.  (b) The chromatograms 
of the HAT after heating for 10 minutes at the indicated temperatures. Thermal profiles of LAT1-
CD98hc in SEC1 buffer in the absence (c) or presence (d) of 50 mM leucine.   
CONCLUSION 
Progress in the structure determination of human membrane proteins has 
been hampered in part by the inefficiency of heterologous expression for their 
production. By using mammalian expression systems such as the HEK293SG system, 
the difficulty of human membrane protein production has been reduced. However 
lower yields when compared to heterologous expression mean that, particularly for 
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the purpose of structural study, protein production remains labour intensive and a 
major bottleneck. I successfully overexpressed LAT1-CD98hc in HEK293SG cells. The 
yields per L of cell culture were between, 0.1 – 0.3 mg, depending of the detergent 
concentration used in the size exclusion buffer. CHS is known to stabilise detergent 
solubilised membrane proteins by two mechanisms, that is by either binding directly 
to the membrane protein and, or by modulating the geometry of the protein-
detergent complex to better mimic the cell membrane (O’Malley et al., 2011). The 
work with purified LAT1-CD98hc is consistent with the modulation of the 
transporter’s activity by membrane cholesterol and the presence of putative 
cholesterol/CHS binding sites on LAT1. The presence of simplified glycans on CD98hc 
represent potential for further optimisation to improve homogeneity of the sample 
without potentially compromising yield. 
Protein crystallography and cryo-EM can be used in parallel and can be 
complementary to each (Vinothkumar and Henderson, 2010; Lander et al., 2012).  
The sample requirement for for homogeneous and stable sample similar in both 
techniques, but buffer composition, amount of sample and the requirement for 
crystals are significant differences (Vinothkumar, 2015). The optimisation reported 
here has so far focused on preparing samples homogeneous and stable enough to 
work with both techniques but further optimisation was required for cryo-EM. The 
presence of glycerol and detergent concentrations 10x higher than the CMC of DDM, 
will most likely contribute to the background noise of any cryo-EM micrographs that 
may be obtained using LAT1-CD98hc samples in the conditions reported here so far 
(Thompson et al., 2016). Work toward a structure by cryo-EM single particle analysis 
is described in the next chapter.  
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Chapter 5 - LAT1-CD98hc structure 
determination by single particle cryo-EM 
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This chapter details the results of efforts toward solving the structure of LAT1-
CD98hc using single particle cryo-electron microscopy. Cryo-EM was used to inform 
further optimisation of the sample preparation described in Chapter 4. Single particle 
processing of collected cryo-EM data yielded a low-resolution structure that was 
interpreted by docking the crystal structure of CD98hc ectodomain and a homology 
model of LAT1. Further single particle analysis revealed previously unreported 
flexibility in the interaction of CD98hc ectodomain and LAT1.  
 
OPTIMISATION OF SAMPLE PREPARATION, IMAGE PROCESSING AND CRYO-
EM DATA COLLECTION 
LAT1-CD98hc was prepared, for initial cryo-EM experiments in the buffers 
optimised and used during biochemical characterisation. Namely, size exclusion 
buffers 1 & 2 (SEC1 and SEC2), both containing 50 mM leucine, 100 mM TrisCl, 300 
mM NaCl and 10 % glycerol at pH 8 but with SEC1 having only x1 the critical micelle 
concentration of DDM with LMNG and CHS (15:5:3) and SEC2 having 10 times that 
concentration of the detergent mix. For cryo-grid preparation “in-house” grids, and 
a custom-built guillotine used for plunge freezing in a humidified cold room (4 °C). 
Grids were imaged on a 300 kV Titan Krios with a Gatan K2 camera and the images 
produced were subjected to down sampling to an Å/px size of 2.3 then contrast 
transfer correction was applied (Figure 34). No large aggregates were visible in the 
micrographs, while small particles consistent with the image collection parameters  
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Figure 34 - Exploratory cryo-EM micrographs of LAT1-CD98hc purified in SEC2 (a) or SEC1 (b) buffer 
obtained at the LMB. Samples were concentrated to 1.1 mg mL-1 before application to cryo-grid, 
blotting and plunge freezing. Images were subject to 2x2 binning and CTF correction, scale bar shown 
is 100 nm. 
and molecular weight of the HAT (123 kDa) were visible and appear evenly 
distributed on the grid. The small number of micrographs did not allow for further 
processing but was sufficient to motivate further work at the Astbury Biostructure 
Laboratory in Leeds.  
 111 
The first large dataset was collected at the University of Leeds from sample 
purified in SEC2 buffer, as this had given the higher yield of pure HAT. 2,452 
micrograph movies were collected. These were whole frame aligned for beam 
induced motion correction using Motion Cor 2.1, then CTF estimation and correction 
was performed on aligned movies without dose weighting using gCTF (Zhang, 2016; 
Zheng et al., 2017). The resulting images were similar to those obtained from the 
LMB, with evenly distributed particles, although a gradient in the ice thickness was 
visible (Figure 35). 2000 particles were manually picked and submitted to reference 
free 2D classification in RELION 2.1 and 2D classes characteristic of the HAT were 
used as references for auto picking the entire micrograph set, yielding 373,916 
particles. After several rounds of 2D classification, almost all the particles had been 
discarded as they were either carbon or ice contaminates. 2D classes that were 
consistent with the HAT, when further classified, yielded what appeared to be 
projections of protein-detergent complexes (Figure 36b) as well as  potentially empty 
detergent micelles (Figure 36a) in almost equal amounts. The geometry of the 
DDM:CHS micelles was consistent with small angle x-ray and neutron scattering 
experiments that predicted an oblate ellipsoid geometry for DDM micelles (Lipfert et 
al., 2007; O’Malley et al., 2011). Based on the observed abundance of empty micelles, 
the detergent concentration was subsequently lowered to the lowest practical 
concentration, x1 CMC of DDM. The limited number of distinct HAT orientations 
represented in the particle set and the small number particles, precluded single 
particle 3D reconstruction of the HAT.  
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Figure 35 - Representative aligned micrograph movies of first large dataset of LAT1-CD98hc in SEC2 at 
(a) ~3.6 and (b) ~2 µM defocus. Sample was concentrated to 1.1 mg ml-1 before application to a 
Quantifoil 2/2 grid, blotting and plunge freezing using a Vitribot instrument. Micrograph movies were 
aligned for beam induced motion correction then CTF corrected.  Scale bar given is 60 nm. 
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Figure 36 - 2D classes of empty detergent micelles and protein detergent complexes from the first large 
dataset of LAT1-CD98hc in SEC2.  (a) Side view projections of oblate ellipsoid detergent micelles. (b) 
2D classes characteristic of a HAT protein detergent complex, with small soluble density and large 
ellipsoidal detergent belt. Particle box size was 200 Å with a mask diameter of 180 Å. 
A second dataset was collected with x1 CMC DDM and 5 % glycerol, as 
glycerol is known to contribute to background scattering, reducing the signal to noise 
ratio (Thompson et al., 2016). The improvement in contrast was obvious and most 
likely due to the lower glycerol. However, the particle distribution on the grid was 
not ideal, with most of the particles clustering near the carbon support (Figure 37). 
The ice appeared to increase in thickness closer to the carbon support. The same 
sample conditions were used to prepare new grids and where the ice thickness, 
particle distribution and contrast was improved by changing the blotting parameters 
and collecting data using a Volta phase plate respectively (Figure 38). The 
improvement in image quality gained from reducing glycerol allowed for generation 
of an initial 3D model by stochastic gradient descent in RELION 2.1, 3D classification 
and 3D auto-refinement. The quality of the resulting 3D reconstructions did not allow 
for a satisfactory docking of the crystal structure of CD98hc’s ectodomain and 
although the phase plate improved the contrast, the background signal was also 
boosted minimising the gains in contrast.  
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SINGLE PARTICLE RECONSTRUCTION AND EM DENSITY MAP INTERPRETATION 
Another dataset was collected using a VPP but with sample prepared in 
glycerol free SEC buffer at x1 CMC DDM and a higher protein concentration of 2.3 mg 
mL-1. The contrast was improved compared to the previous phase plate data with 5 
% glycerol, and there were more particles per image (Figure 39). After whole frame 
beaming induced motion correction and CTF correction, 1388 particles were 
manually picked in RELION 3 and subjected to reference free 2D classification to yield 
2D classes for use as auto picking references. The 2D references were used to auto 
pick 374,941 particles, giving an average of 157 particles per micrograph. Using a 
previously generated initial 3D model low-pass filtered to 60 Å, 3D classification using 
all the particles was done with 2 classes in order to remove “junk” while reducing risk 
of discarding poorly represented orientations of the HAT. After visual inspection, 
191,445 particles that were in one of the two classes were chosen and subjected to 
reference free 2D classification to yield 100 classes, the majority of which were 
protein detergent complex. After 2D classification of this particle set and a 3D 
classification of the particles making up the best 2D classes (Figure 40), 77,423 
particles remained and were used in a 3D auto-refinement yielding a 3D single 
particle reconstruction at 12 Å after post-processing and a B factor sharpening of -
1200 (Figure 41f). The 3D reconstruction was docked with the 2.1 Å crystal structure 
of CD98hc ectodomain using the “fit to segment” tool in Chimera. The cross-
correlation between the map and crystal structure was 0.77, also 96% and 98% of 
crystal structure’s atoms and backbone respectively were included inside the EM 
map after docking suggesting that the results of the 3D reconstruction are consistent 
with the crystal structure. The large lobe of the 3D reconstruction had an “empty” 
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ring like channel presumably demarcating the boundary between the detergent 
micelle and the transmembrane domains of the HAT (Figure 41a – d). This “empty” 
channel is presumably due to flexibility in the hydrophobic tails of the detergent 
monomers, which in principle should face towards and stabilise the hydrophobic 
domains of the protein in the protein detergent complex. The quality of the dataset 
as indicated by the maximum resolution frequency distribution is sufficient for 
achieving a sub-nanometre resolution single particle reconstruction, with ~99% of 
the micrographs falling between 2.5 – 5 Å, and the diversity of projection 
orientations, suggested that flexibility within the sample itself limited the resolution, 
despite improvements gained through optimization (Figure 42).  
The apo-out open model of LAT1 was docked into a segment of the density in 
the larger lobe of the density map, with 99% of all the model’s atoms included inside 
the map there was still some unoccupied density which may be explained by the 
transmembrane domain of CD98hc (Figure 41b). The distance between the C164 in 
the outward open model of LAT1 and G109 substituted for C210 (Uniprot ID: P08195-
1) in the ectodomain structure after docking was 17 ± 2 Å, that is from the N atom of 
one residue to that of the other (Figure 47). Both positions are located on loops and 
are therefore presumably flexible. Figure 43 shows a model of an alternative 
conformation of the linker region, residues 109 – 112, of CD98hc, demonstrating the 
C109 in CD98hc and C164 in LAT1 can be brought into sufficient proximity for the 
disulphide bond to form in the model of the HAT based on the 12 Å EM map. The 
placement of a model of LAT1 in the micellar density was a substantial improvement 
over the previously reported 21 Å structure of a HAT, allowing for structural 
characterization of the quaternary structure of LAT1-CD98hc. 
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Figure 37 - Representative aligned micrograph movies of LAT1-CD98hc in 5% glycerol and x1 CMC of 
DDM at (a) ~1.2 and (b) ~3.4 µM defocus. Sample was prepared with lower glycerol and detergent 
before concentrating to 1.1 mg ml-1, application to a Quantifoil 1.2/1.3 cryo-grid, blotting and plunge 
freezing using a Vitribot instrument. Micrograph movies were aligned for beam induced motion 
correction then CTF corrected. Scale bar given is 60 nm. 
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Figure 38 - Impact of Volta phase plate data on image contrast of LAT1-CD98hc in 5% glycerol and x1 
CMC of DDM. Sample was prepared with lower glycerol and detergent before concentrating to 1.4 mg 
ml-1, application to a Quantifoil 1.2/1.3 cryo-grid, blotting and plunge freezing using a Vitribot 
instrument. Micrograph movies were aligned for beam induced motion correction then CTF corrected. 
Images (a) and (b) are from movies recorded at ~1.9 and ~0.1 µM defocus respectively. Scale bar given 
is 60 nm. 
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Figure 39 - Representative aligned micrographs movies of LAT1-CD98hc in glycerol free buffer at x1 
CMC of DDM collected using Volta phase plate. Sample was concentrated to 2.3 mg ml -1 before 
application to a Quantifoil 1.2/1.3 cryo-grid, blotting and plunge freezing using a Vitribot instrument. 
Micrograph movies were aligned for beam induced motion correction then CTF corrected. Images (a) 
and (b) are from movies captured at ~1.1 and ~0.1 µM defocus respectively. Scale bar given is 60 nm. 
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Figure 40 - Representative 2D classes from glycerol free sample collected using Volta phase plate. A 
variety of projections of the protein detergent complex visible amongst the 2D classes. Particle box 
size was 200 Å with a mask diameter of 180 Å. 
 
  
Figure 41 - 12 Å reconstruction of apo-LAT1-CD98hc in glycerol-free buffer. Coulomb potential map of 
3D reconstruction of LAT1-CD98hc protein-detergent complex shown as a mesh surface in a – c and 
the ectodomain crystal structure of CD98hc and outward open model of LAT1 shown as tan and pink 
ribbons respectively in a – e. (a) is rotated 180 ° in the plane of the page with respect to (b) a bottom 
and top view of the protein-detergent complex. (c) Side view of the docked EM map. (d) Top view of 
a cross section through the long axis of the larger lobe, show as a grey surface, illustrating the quality 
of the docking of the LAT1 model in the EM map. Dimensions of EM map marked by red arrows and 
the distances given in Å. Unoccupied density adjacent to the LAT1 model indicated by * in b and d. (e) 
Models LAT1-CD98hc ectodomain without EM density map (f) Fourier shell correlation vs 1/Å with 
dotted black line to show spatial frequency at correlation 0.143, which was ~12 Å.  
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Figure 42 - Quality of dataset 4 and orientation distribution of 2D projections used in single particle 
reconstruction of LAT1-CD98hc to 12 Å. (a) Histogram of the frequency distribution of micrographs in 
dataset 4 across different maximum resolutions bins. (b) Orientation distribution of LAT1-CD98hc 
projections from dataset 4 used in the 3D reconstruction of 12 Å EM map of the protein-detergent 
complex.  
 
Figure 43 - Modelling conformations of residues 109 – 112 of the CD98hc ectodomain crystal structure 
(PDB ID 2DH2), where disulphide bond forming C210 in CD98hc is located.  (a) Crystal structure of 
CD98hc, residues 109 – 112 coloured by Ca B factor. B factor scale is in Å2 . (b) CD98hc ectodomain 
(blue) and outward open conformation of LAT1 (purple) docked in 12 Å map (mesh). C109 (sticks) of 
CD98hc brought >5 Å of C164 (sticks) LAT1. 
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The extracellular face of LAT2 and the ectodomain of CD98hc have been 
postulated to interact extensively and the residues at the interface have been 
predicted (Rosell et al., 2014).  In the EM map, LAT1 and the ectodomain of CD98hc 
do not interact in a manner similar to LAT2 even though sequence analysis showed 
that putative interaction residues are conserved or substituted for similar ones in 
LAT1 (Figure 44). Out of 19 of these residues only 6 were <10 Å of CD98hc 
ectodomain, in the docked EM map (Table 8; Figure 44). As a means of independent 
validation, LAT1 in the outward open conformation and CD98hc ectodomain were 
docked using ClusPro, with distance restraints inferred from cross-linking 
experiments of LAT2 and CD98hc ectodomain (Rosell et al., 2014). All the predicted 
docking poses did not place CD98hc in better proximity to the predicted interface 
residues and some were implausible as they placed CD98hc ectodomain in regions of 
LAT1 predicted to be membrane embedded. The evidence from the interpretation of 
the EM map and protein-protein docking suggests that LAT1 does not interact with 
CD98hc in a similar fashion to LAT2, in fact the EM docking suggests limited 
interaction between LAT1 and CD98hc ectodomain and therefore CD98hc 
ectodomain may adopt various conformations with respect to LAT1.  
In order to explore possible flexibility between the two subunits, 3D 
multibody auto-refinement was performed using the final 3D auto-refinement that 
produced the 12 Å map as a starting point, followed by principle component analysis 
as described by Nakane et al., 2018. Principal component analysis (PCA) of the 
variance in rotations and translations of the two bodies defined in the multibody 
refinement was accounted for by motion along 12 eigen vectors/principle 
components, with the first three accounting for 42.7% of variance (Figure 46a). 
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Figure 44 – Putative LAT1-CD98hc interface residues. LAT1 (pink ribbon) residues predicted based on 
homology with LAT2, to interact with CD98hc ectodomain are shown as blue spheres. The orientation 
of CD98hc ectodomain (tan ribbon) to LAT1 was predicted based rigid body docking into the 12 Å EM 
of the complex. Residues within <10 Å of CD98hc ectodomain are shown as red spheres. (See also 
Table 8) 
A volume series, consisting of 10 volumes per component, were written out 
for the first 3 components, allowing for visualization of the molecular flexibility 
between the two bodies. The crystal structure of CD98hc ectodomain and outward 
open model of LAT1, were docked in each volume of the series allowing for modelling 
of the flexibility described by the volume series in molecular terms (Figure 45;Figure 
46). Component 1, described 18.7% of the variance, showed mostly translation but 
also some rotation of CD98hc ectodomain and LAT1 in opposite directions along 
parallel planes, perpendicular to the plane of the long axis of the complex (Figure 
46b; Movie 1). The second largest component, which described 13.7% of the 
variance, showed a rocking motion i.e. forward downward but slanted motion in 
CD98hc ectodomain and a downward backward motion in LAT1, with the effect of 
bringing the C domain of CD98hc closer to LAT1 while lifting the A domain away 
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(Figure 46c; Movie 2). The third component showed an upward and downward 
motion in CD98hc ectodomain and a slight twisting motion in LAT1 bringing the two 
closer and further apart from each other (Figure 46d: Movie 3). The flexibility 
described by the principle component analysis was consistent with transient or 
limited interaction between LAT1 and CD98hc ectodomain, which is contrary the 
prediction of extensive interaction based on homology to LAT2. The distance 
between residues that were positive in LAT2-CD98hc cross-linking experiments were 
tracked across each frame of the eigen movies for vectors 1 – 3. All residues tracked 
being > 18 Å apart, outside the range of the cross-linkers (3.5 – 14.3 Å) used by Rosell 
et al., 2014 (Figure 47). However, Gly505 and Ser487 in CD98hc, are located on a 
linking loop comprised of residues with relatively high temperature factors in the 
crystal structure of the ectodomain, while Gly220 and Ser324 in the LAT1 homology 
model are likely to be flexible. They are also located on loops and therefore these 
residues may be within the range of the cross-linkers in some conformations. This 
distance analysis also highlights the dynamic LAT1-CD98hc interaction with residues 
being displaced by as much as 5 Å between various conformations of the HAT. 
 
Figure 45 - CD98hc ectodomain crystal structure docked in improved EM map density. Both a) and b) 
show crystal structure (PDB ID) 2DH2 docked the density corresponding to CD98hc ectodomain which 
had an improved resolution (~9 Å) after multibody refinement. Densities corresponding to A and C 
domains of the ectodomains were visually distinguishable increasing confidence in the interpretation 
of the map by docking. b) is rotated 90 ° anti-clock wise in the plane perpendicular to that of the page, 
relative to a). 
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Figure 46 - Molecular dynamics of LAT1-CD98hc in solution. a) PCA of relative orientations of EM 
densities corresponding to CD98hc ectodomain and the transmembrane domains of CD98hc and 
LAT1, after two body 3D auto-refinement. Molecular flexibility along eigen vectors 1 (b), 2 (c), and 3 
(d). Structures in (c) and (d) are rotated approximately 90 ° anti-clockwise relative to (b) in the plane 
perpendicular to the page. The black arrows indicate the direction of motion from the first to the last 
EM density map of volume series showing motion/flexibility along the given Eigen vector.  
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Table 13 - Residues cross-linked in order to validate in silico docking of LAT2 and 
CD98hc ectodomain crystal structure.  
Distance restraints were obtained from Rosell et al., 2014. The estimated distance between these 
residues and residues in CD98hc ectodomain were calculated from docking of the volume series of 
PCs 1 – 3 for LAT1 to the nearest Å. 
CD98hc  LAT2 LAT1 Distance LAT2 
from cross-
linking (Å) 
Average LAT1 
distance from 
cryo-EM (Å) 
S151 C210 G220 13.4 25 ± 2  
A315 S324 14.9 32 ± 2 
S195 C210 G220 17.5 20 ± 2  
A315 S324 15.5 31 ± 2 
S412 C210 G220 11.5 36 ± 2 
S487 G392 S401 12.9 34 ± 1 
G505 A235 V244 8.4 23 ± 1  
S441 S450 8.1 32 ± 1 
  
 
 
Figure 47 - Distances between residues predicted to be in close proximity based on homology to LAT2. 
The distance between the N atoms of residues in CD98hc ectodomain, designated chain B and LAT1, 
designated chain A, were measured across conformations predicted based on docking of the two 
structure in the frames of “eigen movies” of eigen vectors 1,2 and 3 from the principle component 
analysis of the variance discovered in the multibody refinement of LAT1-CD98hc at 12Å. 
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CONCLUSION 
A high resolution structure of a HAT such as LAT1-CD98hc remains elusive 
despite efforts toward achieving this goal (Fort et al., 2007; Costa et al., 2013; Meury 
et al., 2014; Rosell et al., 2014). Here I report the first attempt at single particle 
analysis of LAT1-CD98hc using cryo-EM. Cryo-EM micrographs of LAT1-CD98hc in 
vitreous ice showed particles of a size consistent with the 123 kDa complex in 
detergent. Excess detergent and glycerol interfered with the single particle 
reconstruction as empty detergent micelles were mistaken for protein detergent 
complexes and glycerol reduced the signal to noise ratio of the particles. The 
elimination of glycerol from the sample and lowering of detergent concentration, 
also improved grid preparation and Volta phase plate data collection, producing a 
data set from which a 12 Å structure of LAT1-CD98hc in detergent was solved. The 
reconstruction was validated by docking the 2.1 Å crystal structure of CD98hc 
ectodomain. This map was sufficiently detailed to allow for docking of a predicted 
model of the outward open conformation of LAT1. There was little density in the EM 
map between LAT1 and CD98hc ectodomain suggesting transient interactions 
between the two. Multibody refinement using RELION 3, followed by principal 
component analysis of the rotations and translations of LAT1 and CD98hc 
ectodomain, revealed variance within the particles that had been assumed to be of 
the same conformation. The flexibility described by the first three eigen vectors of 
the PCA visualised showed CD98hc ectodomain barely interacts with LAT1 and is 
most likely tethered to LAT1 by interactions between the transmembrane domain of 
CD98hc and the conserved disulphide bond. 
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An interaction interface between CD98hc ectodomain and LAT2 was 
proposed on the basis of docking and cross-linking experiments by Rosell et al., 2014. 
LAT2 shares 52% sequence identity with LAT1 and residues at this interface are 
conserved and therefore it was assumed that LAT1 interacted with CD98hc 
ectodomain in a similar manner to LAT2. EM maps reported here and the subsequent 
interpretation of them, do not support this hypothesis. Only 31.6 % of the putative 
interacting residues in LAT1 are < 10 Å away from CD98hc ectodomain and all of the 
residues successfully cross-linked in order to validate the results of in silico docking 
of LAT2 and CD98hc ectodomain, were greater >18 Å apart in each member of the 
LAT1-CD98hc ectodomain model ensemble generated from the cryo-EM data 
presented here.  
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Chapter 6 - General discussion & future 
outlook 
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This chapter serves a final discussion of the main novel finding of this study which 
are:  
- LAT1-CD98hc is modulated and stabilised by cholesterol through putative 
cholesterol binding sites in LAT1. This part of the study was published in 
“Modulation of LAT1 (SLC7A5) transporter activity and stability by membrane 
cholesterol” Scientific Reports volume 7, Article number: 43580 (2017) 
- Inhibitors of LAT1, JPH203, KMH233 and SKN103, are competitive inhibitors 
of the transporter and JPH203 and SKN103 are potentially transported 
substrates while KMH233 may sterically hinder transition from the outward 
open conformation to any of the occluded conformations and thus may not 
be a transported substrate. 
- Cryo-EM of detergent solubilised LAT1-CD98hc shows limited interaction 
between CD98hc ectodomain and LAT1 and thus flexibility between the two 
domains. The interaction of the two is not consistent with modelling of the 
interaction with LAT2. 
 
LAT1-CD98hc is one of the rare heterodimeric solute carrier transporters in 
the human genome and plays key roles in normal and disease physiology as outlined 
in the introduction of this thesis. Understanding the structural details of this amino 
acid transporter’s organisation and function was the overarching aim of the research 
reported here. The cloning of LAT1 was reported in 1998, since and before then there 
have been significant efforts to understand the transporter’s structure and function 
(Kanai et al., 1998; Mastroberardino et al., 1998). There also has been significant 
progress in the structural biology of SLC transporters, particularly the solution of the 
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structures of bacterial homologues of LAT1, EcAdiC and GkApcT, as well as structural 
analogues of eukaryotic origin such as dDAT (Gao et al., 2010; Penmatsa et al., 2013; 
Bai et al., 2017; Jungnickel et al., 2018). Sequence alignment of LAT1 and dDAT 
suggested that the two cholesterol/CHS binding sites observed in the crystal 
structures of dDAT were conserved in LAT1. The residues identified were found 
conserved across several LAT1 orthologues consistent with functional importance. 
Homology modelling of LAT1’s structure revealed a similar organisation of these 
residues in the tertiary structure, lending further credence to the hypothesis of 
LAT1/cholesterol interaction via these conserved residues. The hypothesis was 
tested experimentally by transport assay and cholesterol depletion in cells expressing 
LAT1.  It was shown that cholesterol depletion lowered Vmax but not Km of LAT1 
mediated transport and thus it was concluded cholesterol was acting as an allosteric 
modulator of LAT1 transport (Dickens et al., 2017). Additional putative binding site 
were identified by sequence motif searching for CRAC/CARC motifs. This study adds 
to a growing body of knowledge about the role of lipid bilayers in the functions of 
specific membrane proteins within them. This may have implications for research, 
particularly for in vitro and in silico experiments that seek to model the functions of 
membrane proteins. For example, lipids have proved to be important for the 
preservation of function of solubilized membrane proteins and for their 
crystallization (Banerjee et al., 1995; Guan et al., 2006; Phillips et al., 2009; 
Laganowsky et al., 2014). Drug design may also be impacted as lipids could act as 
templates for the design of allosteric modulators of membrane protein function for 
the treatment of disease.  
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LAT1 mediated transport plays a major role in the survival and progression of 
a variety of cancers and as result this activity has been the focus of chemotherapeutic 
drug development. The binding modes of three LAT1 specific inhibitors was explored 
here using models of LAT1 in the outward facing conformation and in the inward 
facing occluded conformation. SKN103 and JPH203 bound to both conformations 
and had extensive interaction networks compared typical substrates, an observation 
consistent with their predicted binding energies and affinity as inferred from IC50 
calculations. The predicted binding energies were higher for the inward occluded 
conformation compared to the outward open. Their binding in a similar manner to 
substrates to both transporter conformations suggest they may be transportable but 
their favourable binding to one conformation raises the possibility that they may 
inhibit transport by stabilising this favoured conformation, stalling the transporter 
cycle. The design and screening of conformation specific drugs is becoming common 
for the targets like G-protein coupled receptors but is still to be extended to 
transporter drug design. These are question for further research. The inhibitor 
KMH233 behaved atypically and bound only to the outward open conformation by 
binding to a novel putative amino acid binding site. The binding pose of KMH233 was 
such that it would sterically hinder conformational change from the outward open 
to the inward open conformation, disrupting the transport cycle. The two different 
inhibition modes described here could form a basis for more nuanced inhibitor 
design for LAT1, increasing the urgency for experimental validation of these models 
specifically through X-ray crystallography or single particle cryo-EM.  
Membrane proteins are often present in cells, in small quantities insufficient 
for structural study (Ostermeier and Michel, 1997). Although there are solutions to 
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this problem, membrane proteins remain recalcitrant to characterisation by 
structural techniques such as protein crystallography and cryo-electron microscopy 
(Kang et al., 2013; Vinothkumar, 2015). The paucity of membrane proteins in cellular 
material is often addressed by heterologous or overexpression of the protein of 
interest. Escherichia coli is the most popular organism for heterologous expression 
and has worked well with small soluble proteins and the soluble domains of 
membrane proteins. However, prokaryotic expression systems like E.coli, prove less 
efficient or fail to express membrane proteins larger than 35 kDa, with more than 6 
transmembrane helices, regardless of the organism of origin (Terpe, 2006; Nettleship 
et al., 2010; Bernaudat et al., 2011). Additionally, post translational processing such 
as disulphide bond formation and glycosylation, tend to be inefficient or completely 
absent in these systems, leading to expression of unfolded and or non-functional 
proteins (Terpe, 2006).  Yeast are an alternative to bacterial expression that can 
provide similar, albeit with reduced flexibility and ease in manipulation, the requisite 
expression capacity and processing to produce larger membrane proteins that are 
correctly folded and functional (Nettleship et al., 2010).  Saccharomyces cerevisiae 
and Pichia pastoris are two species of yeast commonly used in the production of 
eukaryotic proteins including transmembrane proteins (Joubert et al., 2010; Ahmad 
et al., 2014). Like yeast, insect cells such as those from Spodoptera frugiperda, are 
capable of post-translational modifications such as glycosylation, but differ from 
higher eukaryotes in the exact nature of this glycosylation and in membrane lipid 
composition, meaning the native fold and functionality of the expressed 
transmembrane protein is only more likely but not guaranteed (Nettleship, 2012). 
The insect baculoviral system is more time consuming and expensive compared to 
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yeast, due to the requirement for virus production, titration, the optimisation of the 
insect cell transduction before expression, and because of the cost of growth 
medium used in the culture of the insect cells. Given the disadvantages of insect cell 
expression compared to yeast cell expression, in a situation where near native 
glycosylation is essential, mammalian expression systems such the Chinese hamster 
(CHO) and human embryonic kidney cell-lines (HEK293) are preferable (Dalton and 
Barton, 2014; Büssow, 2015). Membrane protein production in mammalian cells, can 
be technically demanding, as well as labour and resource intensive, relative to 
heterologous expression in bacteria or yeast, and often results in lower protein yields 
(Chaudhary et al., 2012; Klepsch et al., 2011). However once successfully 
overexpressed, the resulting protein is often correctly folded, post-translationally 
modified and thus most likely biochemically active. These advantages often outweigh 
the challenges, and strategies for streamlining expression and increasing yields are 
being developed, as a result mammalian protein production for the structural study 
of human membrane proteins is increasingly becoming popular in structural biology 
(Chaudhary et al., 2012; Aricescu and Owens, 2013; Goehring et al., 2014; Lin et al., 
2015). A protocol for stable mammalian expression and purification of detergent 
solubilised LAT1-CD98hc was developed and optimised. The requirement for CHS in 
the purification buffers during and after membrane solubilisation was consistent 
with the hypothesis detailed above, that’s the modulation of LAT1 by direct 
interaction with cholesterol. The addition of ATM to the lysis buffer was a small but 
important modification to the purification protocol as it maximised the amount of 
purified HAT with the disulphide bond. Although already reported in the literature, it 
will be used regularly in the purification of proteins with structural disulphide bonds 
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from mammalian cells (Kao et al., 2010; Trexler-Schmidt et al., 2010; Koterba et al., 
2012).  
After further sample optimisation, informed by cryo-EM data collection and 
processing, a 12 Å structure of LAT1 was achieved allowing for the docking of the 
crystal structure of CD98hc ectodomain and the outward open conformation of LAT1. 
Given the low SNR ratio of cryo-EM data which requires averaging techniques to 
improve, and the uncertainty of orientation assignment between the 2D projections 
from the data during 3D reconstruction, the final map must be validated to ensure it 
is representative of the structure under investigation (Frank, 2006). Tilt pair analysis, 
which requires collecting a subset of micrographs at two goniometer angles 
generating 2D projections related to each by a known angle. These can be used to 
determine the accuracy of orientation assignment of 2D projections in the final map 
by comparing the angle between matching projections in the final EM map 
(Rosenthal and Henderson, 2003; Rosenthal, 2016). Also, if known consistency 
between an independently determined structure of the same particle or part of it, 
such as crystal structure, may be used to assess the quality of the of the final map 
(Frank, 2006; Henderson et al., 2012; Rosenthal, 2016). The latter approach was 
taken here as no tilt pair data was collected. The crystal structure of CD98hc 
ectodomain docked into the 12 Å EM structure. From the structure reported here it 
is obvious that detergent solubilised LAT1-CD98hc is not a dimer of heterodimers 
even though one of the reported crystal structures of CD98hc ectodomain is a dimer 
(PDB ID 2DH3) and a LAT1 dimer has been suggested on the basis of homology to 
EcAdiC (Fort et al., 2007; Napolitano et al., 2017a). The orientation of CD98hc 
ectodomain in the docking, in fact precludes a CD98hc dimer and LAT1 as it would 
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clash with the plasma membrane. There is also no extensive interaction between the 
CD98hc ectodomain and LAT1 as was described for LAT2-CD98hc by Rosell et al., 
2014. Residues at the predicted interface of LAT2 and CD98hc were found to be 
mostly conserved in LAT1 but less than half of them were less 10 Å away from each 
other in the cryo-EM model LAT1-CD98hc ectodomain. 3D auto refinement of the 
CD98hc ectodomain and micellar density was performed on them as two 
independent rigid bodies followed by PCA of their relative rotations and translations. 
This revealed continuous motion between the two subunits. The flexible motion of 
CD98hc relative to LAT1 is consistent with limited or transient interaction between 
the ectodomain and LAT1. A similar conclusion was reached from the work reported 
by Pfeiffer et al., 1998, using mutagenesis and co-immunoprecipitation. The idea that 
LAT1 and LAT2 may interact differently with CD98hc is not a new one. Bröer et al., 
2001 put forward, based experiments with truncated versions of CD98hc and various 
light chains, including LAT1 and LAT2, that CD98hc is modular requiring different 
modules to interact with different light chains. These experiments showed that, for 
the recognition of LAT1, the cytosolic N terminus and transmembrane domain of 
CD98hc were sufficient for the association of CD98hc and LAT1 whereas LAT2 
required the complete ectodomain domain. Rosell et al., 2014 stated that the 
extracellular vestibule to the substrate binding site was accessible in the model of 
CD98hc ectodomain and LAT2 proposed but it unclear whether the binding of 
CD98hc reduced the volume open to the solvent. This is of interest as it may offer in 
part a molecular mechanism for the LAT1 selectivity of inhibitors such as JPH203, 
which may be too large to access the substrate binding site of LAT2 due to the 
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placement of CD98hc. Even more interesting is the prospect of exploiting this 
difference heavy-light chain interaction for rational drug design. 
The structural characterisation of proteins to atomic or near atomic 
resolution, requires a biochemically homogenous and monodisperse samples 
(Newby et al., 2009). Membrane protein samples which meet these conditions are 
challenging to prepare due to the lipid bilayer embeddedness and amphipathic 
character of these membrane protein systems.  In order to apply techniques common 
for soluble protein purification, such as affinity and size exclusion chromatography, 
the membrane protein or complex in question must first be extracted from its lipid 
bilayer and simultaneously solubilised in aqueous buffer while maintaining its 
functional, native fold. This is often achieved by the use of surfactants such as 
detergent or amphipathic polymers such as styrene maleic acid (SMA) (Lin and 
Guidotti, 2009; Hattori et al., 2012; Stroud et al., 2018).  Detergents are small 
amphipathic molecules that above a certain concentration, the critical micelle 
concentration, form aggregates in aqueous solution referred to as micelles. In 
detergent micelles, the hydrophobic tails of the detergent are sequestered away 
from the aqueous environment external to the micelle, forming a hydrophobic core 
at the centre, while the hydrophilic head groups keep the micelles soluble by 
interacting with the solvent (Linke, 2009). The amphipathic structure of detergent 
monomers is analogous to that of phospholipids and as a result, detergents are 
capable of interacting with and solubilising phospholipid membranes and the 
proteins embedded in them. The hydrophobic core of the micelle mimics the 
hydrophobic centre of a phospholipid bilayer, interacting with the transmembrane 
domains of the detergent solubilised membrane proteins (Le Maire et al., 2000). 
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Detergents vary in the composition of the head and tail groups and thus vary in their 
efficacy in membrane protein solubilisation and stabilisation. They are informally 
classified as being either harsh or mild, depending on whether they are more likely 
to destabilise or stabilise the native fold of a membrane proteins during membrane 
solubilisation. Long chain hydrophobic tailed detergents, usually 10 – 12 carbons, 
with polar head groups such as maltose or glucose, such as n-dodecyl β-D-maltoside 
or n-octyl-β-D-glucoside, are considered mild and are widely used in structural 
studies of membrane proteins. Detergents also differ in the extent to which they co-
extract membrane proteins and their bound lipids with some even enriching for 
particular lipids. For example, the zwitterionic detergent, CHAPS (3-((3-
cholamidopropyl) dimethylammonio)-1-propanesulfonate), has been shown to 
solubilise 4 times more lipids than triton-X100, while enriching the 
phospholipid, phosphatidylethanolamine (Banerjee et al., 1995). Despite these 
generalisations and rules of thumb, the choice of detergent for the purification of a 
given membrane protein or complex, which is an important one because it 
determines the stability and functional state of the purified sample as well as the 
ease or difficulty with which the protein can be structurally characterised,  it is 
difficult to predict a priori a suitable detergent or sometimes cocktail of detergents 
and additives. Therefore significant effort is often spent on screening detergents and 
optimising purification conditions (Arachea et al., 2012; Champeil et al., 2016). In this 
study the effect of detergent solubilisation on the structure of LAT1-CD98hc was not 
explored. Biochemical and biophysical characterisation of the HAT in lipid 
environments such as in nanodiscs, may shed light on the interaction CD98hc and 
LAT1 since it has been hypothesised that CD98hc ectodomain interacts with the 
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plasma membrane (Fort et al., 2007). This putative membrane interaction may play 
a role in the role of CD98hc in the transport cycle of LAT1. 
A high-resolution structure of LAT1-CD98hc remains crucial for further 
understanding the function of the transporter and for placing some of the insight 
gleaned here and in other similar efforts on sound experimental footing. The state of 
the art cryo-EM appears sufficiently advanced for the determination of a structure of 
this complex but heterogeneity in the sample remains a challenge. Expressing a 
fusion construct of LAT1 and BRIL or T4 lysozyme to increase the mass of the 
complex, and potentially help with projection alignments may be necessary (Thal et 
al., 2018). The deletion of CD98hc’s ectodomain using CRISPR Cas9 is also another 
modification that could be made. It would give an opportunity to reproduce the 
experiments of Bröer et al., 2001 in a better model system and if successful would 
remove the heterogeneity of due the ectodomain’s flexibility. Despite some work 
towards it, we could not collect data with ligand bound. Towards this goal, testing of 
the hypotheses generated from the homology modelling and docking is necessary. 
KMH233, if it indeed only interacts with the outward open conformation and 
stabilises it, and also given its affinity and solubility, would be a suitable candidate 
for cryo-EM data collection of ligand bound LAT1-CD98hc. The solution of a high-
resolution structure of LAT1-CD98hc may require a combination of all three but it is 
goal worth of pursuing.  
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